Document:

ex1004k093010.htm

  

  

  

PREFERRED STOCK PURCHASE AGREEMENT

This Preferred Stock Purchase Agreement (“Agreement”) is entered into and effective as of August 25, 2010 (“Effective Date”), by and between Revonergy Inc., a Nevada corporation (“Company”), and Kodiak Capital Group, LLC, a Delaware limited liability company (including its designees, successors and assigns, “Investor”).

RECITALS

A.           The parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue to Investor, and Investor shall purchase from the Company, from time to time as provided herein, up to $500,000.00 of shares of Series A Preferred Stock; and

B.            The offer and sale of the Securities provided for herein are being made without registration under the Act, in reliance upon the provisions of Section 4(2) of the Act, Regulation D promulgated under the Act, and such other exemptions from the registration requirements of the Act as may be available with respect to any or all of the purchases of Securities to be made hereunder.

AGREEMENT

In consideration of the premises, the mutual provisions of this Agreement, and other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, Company and Investor agree as follows:

ARTICLE 1

DEFINITIONS

In addition to the terms defined elsewhere in this Agreement:  (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Certificate of Designations, and (b) the following terms have the meanings indicated in this ARTICLE 1:

“Act” means the Securities Act of 1933, as amended.

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Act.  With respect to Investor, without limitation, any Person owning, owned by, or under common ownership with Investor, and any investment fund or managed account that is managed on a discretionary basis by the same investment manager as Investor will be deemed to be an Affiliate.

“Agreement” means this Preferred Stock Purchase Agreement.

“Bloomberg” means Bloomberg Financial Markets.

“Change in Control” has the meaning set forth within the definition of Fundamental Transaction, below.

“Certificate of Designations” means the certificate to be filed with the Secretary of State of the State of Nevada, in the form attached hereto as Exhibit B.

“Closing” means any one of (i) the Commitment Closing and (ii) each Tranche Closing.

“Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Trading Market, as reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00 p.m., Eastern time, as reported by Bloomberg, or, if the Trading Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such

 

1

  

  

  

 

security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.).  If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and Investor.  If the Company and Investor are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 6.7.  All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

“Commitment Closing” has the meaning set forth in Section 2.2

“Commitment Fee” means a non-refundable fee of $25,000.00 (5% of the Maximum Placement), payable by the Company to Investor in consideration of Investor’s commitment to fund the investment contemplated by this Agreement.  The Commitment Fee is payable in cash on the earlier of 1) the initial Investment Date, in which case the Commitment Fee shall be deducted from the initial Investment Amount, or 2) 3 months from the execution of the Term Sheet.

“Common Shares” means the Warrant Shares.

“Common Stock” means the common stock, par value $0.001 per share, of the Company, and any replacement or substitute thereof, or any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.

“Company Termination” has the meaning set forth in Section 3.2.

“Delisting Event” means any time during the term of this Agreement, that the Common Stock is not listed for and actively and/or regularly trading on a Trading Market, or is suspended or delisted with respect to the trading of the shares of Common Stock on a Trading Market.

“Disclosure Schedules” means the disclosure schedules of the Company delivered concurrently herewith, attached hereto, and incorporated herein by reference.  The Disclosure Schedules shall contain no material non-public information.

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

“Fundamental Transaction” means and shall be deemed to have occurred at such time upon any of the following events:

(i)           a consolidation, merger or other business combination or event or transaction, except for the transactions set forth on Schedule A to the Disclosure Schedule, following which the holders of Common Stock immediately preceding such consolidation, merger, combination or event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company (a “Change in Control”);

(ii)          the sale or transfer of all or substantially all of the Company’s assets, other than in the ordinary course of business; or

 

 

(iii)         a purchase, tender or exchange offer made to the holders of the outstanding shares of Common Stock.

 

 

“GAAP” means United States generally accepted accounting principles applied on a consistent basis during the periods involved.

 

2

  

  

  

 

“Indebtedness” means (a) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of any lease payments in excess of $100,000 due under leases required to be capitalized in accordance with GAAP.

 

“Liens” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Lock-Up Agreements” means an agreement in the form attached as Exhibit C, executed by each of the Company’s officers, directors and beneficial owners of 10% or more of the Common Stock, precluding each such Person from participating in any sale of the Common Stock from the Tranche Notice Date through the Tranche Closing Date.

 

“Material Adverse Effect” means any material adverse effect on (i) the legality, validity or enforceability of any Transaction Document, (ii) the results of operations, assets, business, prospects or financial condition of the Company and the Subsidiaries, taken as a whole, or (iii) a the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document.

 

“Material Agreement” means any material loan agreement, financing agreement, equity investment agreement or securities instrument to which Company is a party, any agreement or instrument to which Company and Investor or any Affiliate of Investor is a party, and any other material agreement listed, or required to be listed, on any of Company’s reports filed or required to be filed with the SEC, including without limitation Forms 10-K, 10-Q or 8-K.

 

“Maximum Placement” means $500,000.00.

 

“Maximum Tranche Amount” means, subject to any other applicable limitations set forth in this Agreement, the Maximum Placement less the amount of any previously noticed and funded Tranches.

“Officer’s Closing Certificate” means a certificate in customary form reasonably acceptable to Investor, executed by an authorized officer of the Company.

 

“Opinion” means an opinion from Company’s independent legal counsel, in the form attached as Exhibit D or in such other form agreed upon by the parties, to be delivered in connection with the Commitment Closing and any Tranche Closing.

 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Preferred Shares” means shares of Series A Preferred Stock of the Company provided for in the Certificate of Designations, to be issued to Investor pursuant to this Agreement.

 

“Prospectus” includes each prospectus and prospectus supplement (within the meaning of the Act) related to the sale or offering of any Common Shares, including without limitation any prospectus or prospectus supplement contained within the Registration Statement.

 

“Registration Statement” means a valid, current and effective registration statement registering for resale the shares of Common Stock to be issued as Warrant Shares hereunder, and except where the context otherwise requires, means such registration statement, as amended, including (i) all documents filed as a part thereof or incorporated by reference therein, and (ii) any information contained or incorporated by reference in a prospectus filed with the SEC in connection with such registration statement, to the extent such information is deemed under the Act to be part of such registration statement.

 

3

  

  

  

 

“Regulation D” means Regulation D promulgated under the Act.

 

“Required Approval” means any approval of the Trading Market or the Company’s stockholders required to be obtained by Company prior to issuing the Securities pursuant to any applicable rules of the Trading Market.

 

“Required Tranche Documents” has the meaning set forth in Section 2.3(e).

 

“Rule 144” means Rule 144 promulgated by the SEC pursuant to the Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect.

 

“Rule 144 Eligible” means eligible for immediate resale under Rule 144 without limitation on the amount of securities sold under Rule 144(e) and without requiring discharge by payment in full of any promissory notes given to the Company prior to the sale of the securities under Rule 144(d)(2)(iii).

 

“SEC” means the United States Securities and Exchange Commission.

 

“SEC Reports” includes all reports required to be filed by the Company under the Act and/or the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the Effective Date (or such shorter period as the Company was required by law to file such material) and for the period in which this Agreement is in effect.

 “Securities” includes the Warrant, the Common Shares and the Preferred Shares issuable pursuant to this Agreement.

 

“Subsidiary” means any Person the Company owns or controls, or in which the Company, directly or indirectly, owns a majority of the capital stock or similar interest that would be disclosable pursuant to Regulation S-K, Item 601(b)(21).

 

“Term Sheet” means shall mean an executed instrument between the parties hereto containing the terms of this and other agreements between the parties, and is hereby incorporated by reference.

“Termination” has the meaning set forth in Section 3.1.

 

“Termination Date” means the earlier of (i) the date that is the six-month anniversary of the Effective Date, or (ii) the Tranche Closing Date on which the sum of the aggregate Tranche Purchase Price for all Tranche Shares equals the Maximum Placement.

 

“Termination Notice” has the meaning as set forth in Section 3.2.

“Trading Day” means any day on which the Common Stock is traded on the Trading Market; provided that it shall not include any day on which the Common Stock is (a) scheduled to trade for less than 5 hours, or (b) suspended from trading.

 

“Trading Market” means the OTC Bulletin Board, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE Amex, or the New York Stock Exchange, whichever is at the time the principal trading system, exchange or market for the Common Stock, but does not include the Pink Sheets inter-dealer electronic quotation and trading system.

 

“Tranche” has the meaning set forth in Section 2.3(a).

 

“Tranche Amount” means the amount of any individual purchase of Preferred Shares under this Agreement, as specified by the Company, and shall not exceed the Maximum Tranche Amount.

 

“Tranche Closing” has the meaning set forth in Section 2.3(f)(iv).

 

4

  

  

  

 

 

“Tranche Closing Date” has the meaning set forth in Section 2.3(f)(i).

 

“Tranche Notice” has the meaning set forth in Section 2.3(b).

 

“Tranche Notice Date” has the meaning set forth in Section 2.3(b).

 

“Tranche Purchase Price” has the meaning set forth in Section 2.3(b), and shall be specified in writing by the Company.

 

“Tranche Share Price” means $10.00 per Preferred Share.  The Company may not issue fractional Preferred Shares.

“Tranche Shares” means the Preferred Shares that are purchased by Investor pursuant to a Tranche.  For the Maximum Placement, the Company shall issue 50,000 Preferred Shares to Investor.

 

“Transaction Documents” means this Agreement, the other agreements and documents referenced herein, and the exhibits and schedules hereto and thereto.

 

“Transfer Agent” means Empire Stock Transfer Inc. or any successor transfer agent for the Common Stock.

 

“VWAP” means, for any date, the volume-weighted average price, calculated by dividing the aggregate value of Common Stock traded on the Trading Market (price multiplied by number of shares traded) by the total volume (number of shares) of Common Stock traded on the Trading Market for such date, or the nearest preceding Trading Day.

 

“Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrant.

 

“Warrant” means the warrant issuable under this Agreement, in the form attached hereto as Exhibit A, to purchase shares of Common Stock with an aggregate exercise price equal to 135% of the Maximum Placement (subject to adjustment as set forth therein).

 

 

ARTICLE 2

PURCHASE AND SALE

 

 

2.1           Agreement to Purchase.  Subject to the terms and conditions herein and the satisfaction of the conditions to closing set forth in this ARTICLE 2:

 

(a)          Investor hereby agrees to purchase such amounts of Preferred Shares as the Company may, in its sole and absolute discretion, from time to time elect to issue and sell to Investor according to one or more Tranches pursuant to Section 2.3 below; and

 

(b)          The Company agrees to pay the Commitment Fee and to issue the Preferred Shares, the Common Shares and the Warrant to Investor as provided herein.

 

2.2           Investment Commitment

 

(a)          Investment Commitment.  The closing of this Agreement (the “Commitment Closing”) shall be deemed to occur when this Agreement has been duly executed by both Investor and the Company, and the other Conditions to the Commitment Closing set forth in Section 2.2(c) have been met.

(b)          Commitment Fee Shares.

INTENTIONALLY OMITTED FROM THIS DOCUMENT

 

5

  

  

  

 

 

(c)          Conditions to Investment Commitment.  As a condition precedent to the Commitment Closing, all of the following (the “Conditions to Commitment Closing”) shall have been satisfied prior to or concurrently with the Company’s execution and delivery of this Agreement:

 

(i)           the following documents shall have been delivered to Investor:  (A) this Agreement, executed by the Company; (B) a Secretary’s Certificate as to (x) the resolutions of the Company’s board of directors authorizing this Agreement and the Transaction Documents, and the transactions contemplated hereby and thereby, and (y) a copy of the Company’s current Articles of Incorporation and other governing documents; (C) the Certificate of Designations executed by the Company and filed with the Nevada Secretary of State; (D) the Opinion; and (E) a copy of (1) the Company’s press release (if any) announcing the transactions contemplated by this Agreement; and (F) a copy of the Company’s Current Report on Form 8-K, as filed with the SEC, describing the transaction contemplated by, and attaching a complete copy of, the Transaction Documents;

(ii)          other than for losses incurred in the ordinary course of business, there has not been any Material Adverse Effect on the Company since the date of the last SEC Report filed by the Company, including but not limited to incurring material liabilities;

(iii)         the representations and warranties of the Company in this Agreement shall be true and correct in all material respects and the Company shall have delivered an Officer’s Closing Certificate to such effect to Investor, signed by an officer of the Company;

(iv)         the Warrant to purchase shares of Common Stock with an aggregate exercise price equal to 135% of the Maximum Placement (subject to adjustment as set forth therein) shall have been delivered to Investor; and

(v)          any Required Approval has been obtained.

(d)          Investor’s Obligation to Purchase.  Subject to the prior satisfaction of all conditions set forth in this Agreement, following Investor’s receipt of a validly delivered Tranche Notice, Investor shall be required to purchase from the Company a number of Tranche Shares equal to the permitted Tranche Share Amount, in the manner described below.

2.3           Tranches to Investor

(a)          Procedure to Elect a Tranche.  Subject to the Maximum Tranche Amount, the Maximum Placement and the other conditions and limitations set forth in this Agreement, at any time beginning on the effective date of this Agreement, the Company may, in its sole and absolute discretion, elect to exercise one or more individual purchases of Preferred Shares under this Agreement (each a “Tranche”) according to the following procedure.

(b)          Delivery of Tranche Notice.  The Company shall deliver an irrevocable written notice (the “Tranche Notice”), in the form attached hereto as Exhibit E, to Investor stating that the Company shall exercise a Tranche and stating the number of Preferred Shares which the Company will sell to Investor at the Tranche Share Price, and the aggregate purchase price for such Tranche (the “Tranche Purchase Price”).  A Tranche Notice delivered by the Company to Investor by 4:30 p.m. Eastern time on any Trading Day shall be deemed delivered on the same day.  A Tranche Notice delivered by the Company to Investor after 4:30 p.m. Eastern time on any Trading Day, or at any time on a non-Trading Day, shall be deemed delivered on the next Trading Day.  The date that the Tranche Notice is deemed delivered is the “Tranche Notice Date.”  Each Tranche Notice shall be delivered via facsimile or electronic mail, with confirming copy by overnight carrier, in each case to the address set forth in Section 6.2.  Except for the first Tranche Closing, the Company may not give a Tranche Notice unless the Tranche Closing for the prior Tranche has occurred or has been cancelled by the Company pursuant to Section 2.3(g).

(c)          Warrant.  On each Tranche Notice Date, that portion of the Warrant equal to 135% of the Tranche Amount shall vest and become exercisable, and such vested portion may be exercised at any time on or after such Tranche Notice Date.  Any portion of the Warrant that becomes exercisable in connection with the delivery of the

 

6

  

  

  

 

Tranche Notice and is exercised by Investor in accordance with Section 1.1 of the Warrant shall be deemed exercised (i) on the applicable Tranche Notice Date, if the Company receives the Exercise Delivery Documents from Investor by 6:30 p.m. Eastern time on the Tranche Notice Date, or (ii) on the next Trading Day, if the Company receives the Exercise Delivery Documents from Investor after 6:30 p.m. Eastern Time on the applicable Tranche Notice Date or on any subsequent date.

(d)          Conditions Precedent to Right to Deliver a Tranche Notice.  The right of the Company to deliver a Tranche Notice is subject to the satisfaction (or written waiver by Investor in its sole discretion), on the date of delivery of such Tranche Notice, of each of the following conditions:

(i)           the Common Stock shall be listed for and currently trading on the Trading Market, and to the Company’s knowledge there is no notice of any suspension or delisting with respect the trading of the shares of Common Stock on such Trading Market;

(ii)          the representations and warranties of the Company set forth in this Agreement shall be true and correct in all material respects as if made on such date (except for any representations and warranties that are expressly made as of a particular date, in which case such representations and warranties shall be true and correct as of such particular date), and no default shall have occurred under this Agreement, or any other agreement with Investor or any Affiliate of Investor, or any other Material Agreement, and the Company shall deliver an Officer’s Closing Certificate to such effect to Investor, signed by an officer of the Company;

(iii)         other than losses incurred in the ordinary course of business, there has been no Material Adverse Effect on the Company since the Commitment Closing;

(iv)         the Company is not, and will not be as a result of the applicable Tranche, in default of this Agreement, any other agreement with Investor or any Affiliate of Investor, or any other Material Agreement;

(v)          there is not then in effect any law, rule or regulation prohibiting or restricting the transactions contemplated in this Agreement or any other Transaction Document, or requiring any consent or approval which shall not have been obtained, nor is there any pending or threatened proceeding or investigation which may have the effect of prohibiting or adversely affecting any of the transactions contemplated by this Agreement; no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or adopted by any court or governmental authority of competent jurisdiction that prohibits the transactions contemplated by this Agreement, and no actions, suits or proceedings shall be in progress, pending or, to the Company’s knowledge threatened, by any person (other than Investor or any Affiliate of Investor), that seek to enjoin or prohibit the transactions contemplated by this Agreement;

(vi)         all Common Shares shall have been timely delivered at the times provided for in this Agreement, including all Warrant Shares issuable pursuant to any Exercise Notice delivered to Company prior to the Tranche Notice Date;

(vii)        Company is in compliance with all requirements to maintain its then-current listing on the Trading Market;

(viii)       Company has a sufficient number of duly authorized shares of Common Stock reserved for issuance in such amount as may be required to fulfill its obligations pursuant to the Transaction Documents and any outstanding agreements with Investor and any Affiliate of Investor, including without limitation all Warrant Shares issuable upon exercise of the Warrant issued in connection with such Tranche;

(ix)         Company has provided notice of its delivery of the Tranche Notice to all signatories of a Lock-Up Agreement as required under the Lock-Up Agreement;

 

7

  

  

  

 

 

(x)           for any Tranche Notice delivered after the earlier of (A) the first Tranche Closing, or (B) the one-month anniversary of the Effective Date, Investor shall have previously received the Commitment Fee.

(e)          Documents to be Delivered at Tranche Closing.  The Closing of any Tranche and Investor’s obligations hereunder shall additionally be conditioned upon the delivery to Investor of each of the following (the “Required Tranche Documents”) on or before the applicable Tranche Closing Date:

(i)           a number of Preferred Shares equal to the Tranche Purchase Price divided by the Tranche Share Price shall have been delivered to Investor or an account specified by Investor for the Tranche Shares;

(ii)          the following executed documents:  Opinion, Officer’s Certificate and Lock-Up Agreements;

(iii)         all Warrant Shares shall have been timely delivered in accordance with any Exercise Notice delivered to Company prior to the Tranche Closing Date; and

(iv)         all documents, instruments and other writings required to be delivered by the Company to Investor on or before the Tranche Closing Date pursuant to any provision of this Agreement or in order to implement and effect the transactions contemplated herein.

(f)           Mechanics of Tranche Closing.

(i)           Each of the Company and Investor shall deliver all documents, instruments and writings required to be delivered by either of them pursuant to Section 2.3(e) of this Agreement at or prior to each Tranche Closing.  Subject to such delivery and the satisfaction of the conditions set forth in Section 2.3(c) as of the Tranche Closing Date, the closing of the purchase by Investor of Preferred Shares shall occur by 5:00 p.m. Eastern time, on the date which is 10 (ten) Trading Days following (and not counting) the Tranche Notice Date (each a “Tranche Closing Date”) at the offices of Investor.

(ii)          If any portion of the Warrant is exercised by Investor on or after the Tranche Notice Date and prior to or on the Tranche Closing Date (which exercise shall be effected by Investor sending the Exercise Delivery Documents to the Company in accordance with Section 1.1 of the Warrant), the Company shall send Investor an electronic copy of its share issuance instructions to the Transfer Agent and shall cause the requisite number of Warrant Shares to be credited to Investor’s account with DTC as DWAC Shares by 12:00 p.m. Eastern time on the Trading Day after the date the Company receives the Exercise Delivery Documents from Investor.

(iii)         On or before each Tranche Closing Date, Investor shall deliver to the Company, in cash or immediately available funds, the Tranche Purchase Price to be paid for such Tranche Shares.

(iv)         The closing (each a “Tranche Closing”) for each Tranche shall occur on the date that both (i) the Company has delivered to Investor all Required Tranche Documents, and (ii) Investor has delivered to the Company the Tranche Purchase Price.

2.4           Limitation on Obligations to Purchase and Sell.  Notwithstanding any other provision, in the event the Closing Bid Price of the Common Stock during any one or more of the 10 Trading Days following the Tranche Notice Date is below 20.0% of the initial exercise price of the Warrant issued on the Effective Date, except as otherwise agreed in writing between the Company and Investor, the Investor may, at its option, decline to purchase any Tranche Shares on the Tranche Closing Date.

 

8

  

  

  

 

 

2.4           Maximum Placement.  Investor shall not be obligated to purchase any additional Tranche Shares once the aggregate Tranche Purchase Price paid by Investor equals the Maximum Placement.

2.5           Share Sufficiency.  On or before the date on which any portion of the Warrant become exercisable, the Company shall have a sufficient number of duly authorized shares of Common Stock for issuance in such amount as may be required to fulfill its obligations pursuant to the Transaction Documents and any outstanding agreements with Investor and any Affiliate of Investor.

ARTICLE 3

TERMINATION

3.1           Termination.  The Investor may elect to terminate this Agreement and the Company’s right to initiate subsequent Tranches to Investor under this Agreement (each, a “Termination”) upon the occurrence of any of the following:

(a)          if, at any time, either the Company or any director or executive officer of the Company has engaged in a transaction or conduct related to the Company that has resulted in (i) a SEC enforcement action, including without limitation such director or executive officer being sanctioned by the SEC, or (ii) a civil judgment or criminal conviction for fraud or misrepresentation, or for any other offense that, if prosecuted criminally, would constitute a felony under applicable law;

(b)          on any date after a Delisting Event that lasts for an aggregate of 20 Trading Days during any calendar year;

(c)          if at any time the Company has filed for and/or is subject to any bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for relief under any bankruptcy law or any law for the relief of debtors instituted by or against the Company or any Subsidiary of the Company;

(d)          the Company is in breach or default of any Material Agreement, which breach or default could have a Material Adverse Effect;

(e)          the Company is in breach or default of this Agreement, any Transaction Document, or any agreement with Investor or any Affiliate of Investor;

(f)           upon the occurrence of a Fundamental Transaction;

(g)          so long as any Preferred Shares are outstanding, the Company effects or publicly announces its intention to create a security senior to the Series A Preferred Stock, or substantially altering the capital structure of the Company in a manner that materially adversely affects the rights or preferences of the Series A Preferred Stock except as disclosed in this Agreement or in a schedule; and

 

(h)          on the Termination Date.

3.2           Company Termination.  The Company may at any time in its sole discretion terminate (a “Company Termination”) this Agreement and its right to initiate future Tranches by providing thirty (30) days advance written notice (“Termination Notice”) to Investor.

3.3           Effect of Termination.  Except as otherwise provided herein, the termination of this Agreement will have no effect on any Common Shares, Preferred Shares, Warrant, or Warrant Shares previously issued, delivered or credited, or on any then-existing rights of any holder thereof; provided, however, upon termination of this Agreement, any outstanding but unexercised portions of the Warrant shall be automatically cancelled.  Notwithstanding any other provision of this Agreement and regardless of whether the first Tranche has closed, the Commitment Fee is payable despite any termination of this Agreement and all fees paid to Investor or its counsel are non-refundable.

 

9

  

  

  

 

ARTICLE 4

REPRESENTATIONS AND WARRANTIES

4.1           Representations and Warranties of the Company.  Except as set forth under the corresponding section of the Disclosure Schedules, which shall be deemed a part hereof and which shall not contain any material non-public information, the Company hereby represents and warrants to, and as applicable covenants with, Investor as of each Closing:

(a)          Subsidiaries.  All of the direct and indirect subsidiaries of the Company are set forth on Section 4.1(a) to the Disclosure Schedule.  All entities with which the Company is presently in discussion with regarding a potential acquisition or similar transaction are set forth under Section 4.1(a) to the Disclosure Schedule.  The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary, and all of such directly or indirectly owned capital stock or other equity interests are owned free and clear of any Liens.  All the issued and outstanding shares of capital stock of each Subsidiary are duly authorized, validly issued, fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

(b)          Organization and Qualification.  Each of the Company and each Subsidiary is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, as applicable, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.  Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.  Each of the Company and each Subsidiary is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

(c)          Authorization; Enforcement.  The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder or thereunder.  The execution and delivery of each of the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby or thereby have been duly authorized by all necessary action on the part of the Company and no further consent or action is required by the Company other than the filing of the Certificate of Designations.  Each of the Transaction Documents has been, or upon delivery will be, duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.  Neither the Company nor any Subsidiary is in violation of any of the provisions of its respective certificate or articles of incorporation, by-laws or other organizational or charter documents.

 

(d)          No Conflicts.  The execution, delivery and performance of the Transaction Documents by the Company, the issuance and sale of the Securities and the consummation by the Company of the other transactions contemplated thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, articles of association, bylaws, or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,

 

10

  

  

  

 

debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected, or (iv) conflict with or violate the terms of any agreement by which the Company or any Subsidiary is bound or to which any property or asset of the Company or any Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(e)          Filings, Consents and Approvals.  Neither the Company nor any Subsidiary is required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than the filing of the Certificate of Designations and required federal and state securities filings and such filings and approvals as are required to be made or obtained under the applicable Trading Market rules in connection with the transactions contemplated hereby, each of which has been, or (if not yet required to be filed) shall be, timely filed.

(f)           Issuance of the Securities.  The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens.  The Company has reserved from its duly authorized capital stock a number of shares of Common Stock and Preferred Stock for issuance of the Securities at least equal to the number of Securities which could be issued pursuant to the terms of the Transaction Documents, based on the then-anticipated exercise prices of the Warrant.

(g)          Capitalization.  The Company is currently authorized to issue 100,000,000 shares of Common Stock, 58,508,333 of which are currently issued and outstanding.  When the Company’s Amended and Restated Articles of Incorporation, which have been approved by the Company’s Board of Directors and stockholders and filed with the Secretary of State of the State of Nevada, become effective on September 6, 2010, the Company will be authorized to issue 500,000,000 shares of Common Stock and 50,000,000 shares of preferred stock.  There are no shares of preferred stock issued or outstanding.  Other than as set forth in Section 4.1(g) to the Disclosure Schedule, the Company has not issued any capital stock since the date of filing of the Company’s most recent quarterly report on Form 10-Q.  No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.  Except as a result of the purchase and sale of the Securities or as set forth in the SEC Reports or on Section 4.1(g) to the Disclosure Schedule, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or securities convertible into or exercisable for shares of Common Stock.  The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than Investor) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange, or reset price under such securities.  All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.  No further approval or authorization of any stockholder, the Board of Directors of the Company or others is required for the issuance and sale of the Securities.  Except as set forth in the SEC Reports, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

(h)          SEC Reports; Financial Statements.  Except as set forth on Section 4.1(h) to the Disclosure Schedule, the Company has filed all required SEC Reports for the two years preceding the Effective Date (or such shorter period as the Company was required by law to file such SEC Reports) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.  As of their respective dates, the SEC Reports complied in all

 

11

  

  

  

 

material respects with the requirements of the Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(i)           Material Changes.  Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in the SEC Reports and on Section 4(i) to the Disclosure Schedule, (i) there has been no event, occurrence or development that has had, or that could reasonably be expected to result in, a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice, and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity incentive plans as disclosed in the SEC Reports.  The Company does not have pending before the SEC any request for confidential treatment of information.

(j)           Litigation.  Except as specifically disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”), which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities, or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.  Neither the Company nor any Subsidiary, nor to the knowledge of the Company any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer of the Company.  The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Act.

(k)          Labor Relations.  No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect.

(l)           Compliance.  Neither the Company nor any Subsidiary (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other similar agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) is or has

 

12

  

  

  

 

been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business, except in each case under clauses (i)-(iii) above as could not have a Material Adverse Effect.

(m)         Regulatory Permits.  The Company and each Subsidiary possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.

(n)          Title to Assets.  The Company and each Subsidiary have good and marketable title in fee simple to all real property owned by them that is material to the business of the Company and each Subsidiary and good and marketable title in all personal property owned by them that is material to the business of the Company and each Subsidiary, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and each Subsidiary and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties.  Any real property and facilities held under lease by the Company and each Subsidiary are held by them under valid, subsisting and enforceable leases of which the Company and each Subsidiary are in compliance.

(o)          Patents and Trademarks.  The Company and each Subsidiary have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses and other similar rights that are necessary or material for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).  Neither the Company nor any Subsidiary has received a written notice that the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights of any Person.  To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights of the Company or each Subsidiary.

(p)          Insurance.  The Company and each Subsidiary are insured as needed by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and each Subsidiary are engaged.  To the best of Company’s knowledge, such insurance contracts and policies are accurate and complete.  Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

(q)          Transactions with Affiliates and Employees.  Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $100,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for other employee benefits, including stock option agreements under any equity incentive plan of the Company.

 

(r)           Sarbanes-Oxley; Internal Accounting Controls.  The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 that are applicable to it as of the date of the Commitment Closing.  The Company and each Subsidiary maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.  The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiaries, is made known to the certifying

 

13

  

  

  

 

officers by others within those entities, particularly during the period in which the Company’s most recently filed periodic report under the Exchange Act, as the case may be, is being prepared.  The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the date prior to the filing date of the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”).  The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the Company’s disclosure controls and procedures based on their evaluations as of the Evaluation Date.  Since the Evaluation Date, there have been no significant changes in the Company’s internal accounting controls or its disclosure controls and procedures or, to the Company’s knowledge, in other factors that could materially affect the Company’s internal accounting controls or its disclosure controls and procedures.

(s)          Certain Fees.  Except for the payment of the Commitment Fee, no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement.  Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section 4.1(s) that may be due in connection with the transactions contemplated by this Agreement or the other Transaction Documents.

 

(t)           Private Placement.  Assuming the accuracy of Investor representations and warranties set forth in Section 4.2, no registration under the Act is required for the offer and sale of the Securities by the Company to Investor as contemplated hereby.  The issuance and sale of the Securities hereunder does not contravene the rules and regulations of any Trading Market.

 

(u)          Investment Company.  The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.  The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act.

 

(v)          Registration Rights.  No Person (other than Investor pursuant to the Transaction Documents) has any right to cause the Company to effect the registration under the Act of any securities of the Company.

 

(w)         Listing and Maintenance Requirements.  The Common Stock is registered pursuant to Section 12 of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating such registration.  The Company has not, in the 12 months preceding the Effective Date, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market.  The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

 

(x)          Application of Takeover Protections.  The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti takeover provision under the Company’s Certificate of Incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to Investor as a result of Investor and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation the Company’s issuance of the Securities and Investor’s ownership of the Securities.

 

14

  

  

  

 

 

(y)          Disclosure; Non-Public Information.  Except with respect to the information that will be, and to the extent that it actually is timely publicly disclosed by the Company pursuant to Section 2.2(c)(i), and notwithstanding any other provision in this Agreement or the other Transaction Documents, neither the Company nor any other Person acting on its behalf has provided Investor or its agents or counsel with any information that constitutes or might constitute material, non-public information, including without limitation this Agreement and the Exhibits, Appendices and Schedules hereto, unless prior thereto Investor shall have executed a written agreement regarding the confidentiality and use of such information.  The Company understands and confirms that neither Investor nor any Affiliate of Investor shall have any duty of trust or confidence that is owed directly, indirectly, or derivatively to the Company or the shareholders of the Company or to any other Person who is the source of material non-public information regarding the Company.  No information contained in the Disclosure Schedules constitutes material non-public information.  There is no adverse material information regarding the Company that has not been publicly disclosed.  The Company understands and confirms that Investor will rely on the foregoing representations and covenants in effecting transactions in securities of the Company.  All disclosure provided to Investor regarding the Company, its business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, furnished by or on behalf of the Company with respect to the representations and warranties made herein are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

 

(z)          No Integrated Offering.  Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Act or which could violate any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the Trading Market.

 

(aa)        Financial Condition.  Based on the financial condition of the Company as of the date of the Commitment Closing:  the Company’s assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company and projected capital requirements and capital availability thereof.  Except as set forth on Section 4(aa) to the Disclosure Schedule, the Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).  The Company has no knowledge of any facts or circumstances that lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the date of the Commitment Closing.  The SEC Reports set forth as of the dates thereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments.  Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.  In connection with the transactions contemplated by the Transaction Documents, the Company (i) did not and does not have any intent to hinder, delay, or defraud any of its creditors, (ii) had a valid business reason for such transactions, (iii) received new value therefor and consideration therefor constituting reasonably equivalent value and fair market value consideration, and (iv) was not rendered insolvent by such transactions and, after giving effect to such transactions, is able to pay its debts as they mature.

(bb)       Tax Status.  The Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.  There are no unpaid taxes in any material amount claimed

 

15

  

  

  

 

to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.  The Company has not executed a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign, federal, state or local tax.  None of the Company’s tax returns is presently being audited by any taxing authority.

 

(cc)        No General Solicitation or Advertising.  Neither the Company nor, to the knowledge of the Company, any of its directors or officers (i) has conducted or will conduct any general solicitation (as that term is used in Rule 502(c) of Regulation D) or general advertising with respect to the sale of the Securities, or (ii) made any offers or sales of any security or solicited any offers to buy any security under any circumstances that would require registration of the Securities under the Act or made any “directed selling efforts” as defined in Rule 902 of Regulation S.

 

(dd)       Foreign Corrupt Practices.  Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any corrupt funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

(ee)        Acknowledgment Regarding Investor’s Purchase of Securities.  The Company acknowledges and agrees that Investor is acting solely in the capacity of arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby.  The Company further acknowledges that Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by Investor or any of its representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to Investor’s purchase of the Securities.  The Company further represents to Investor that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

(ff)          Accountants.  The Company’s accountants are set forth in the SEC Reports and such accountants are an independent registered public accounting firm as required by the Act.

 

(gg)        No Disagreements with Accountants and Lawyers.  There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the accountants and lawyers formerly or presently employed by the Company, and the Company is current with respect to any fees owed to its accountants and lawyers, except for any past-due amounts that may be owed in the ordinary course of business.

 

(hh)        Registration Statements and Prospectuses.

 

(i)           The offer and sale of the Common Shares as contemplated hereby complies with the requirements of Rule 415 under the Act.

(ii)          The Company has not, directly or indirectly, used or referred to any “free writing prospectus” (as defined in Rule 405 under the Act) except in compliance with Rules 164 and 433 under the Act.

 

(ii)          Section 5 Compliance.  No representation or warranty or other statement made by Company in the Transaction Documents contains any untrue statement or omits to state a material fact necessary to make any of them, in light of the circumstances in which it was made, not misleading.  The Company is not aware of any facts or circumstances that would cause the transactions contemplated by the Transaction Documents, when consummated, to violate Section 5 of the Act or other federal or state securities laws or regulations.

 

16

  

  

  

 

The Investor acknowledges and agrees that the Company does not make or has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Section 4.1.

4.2           Representations and Warranties of Investor.  Investor hereby represents and warrants as of the Effective Date as follows:

 

(a)          Organization; Authority.  Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full right, company power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations thereunder.  The execution, delivery and performance by Investor of the transactions contemplated by this Agreement have been duly authorized by all necessary company or similar action on the part of Investor.  Each Transaction Document to which it is a party has been (or will be) duly executed by Investor, and when delivered by Investor in accordance with the terms hereof, will constitute the valid and legally binding obligation of Investor, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b)          Investor Status.  At the time Investor was offered the Securities, it was, and at the Effective Date it is an “accredited investor” as defined in Rule 501(a) under the Act.

 

(c)          Experience of Investor.  Investor, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment.  Investor is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(d)          General Solicitation.  Investor is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

(e)          Access to Information.  Investor confirms that it has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the Securities, including the SEC Reports.  Investor further confirms that it has had an opportunity to ask questions and receive answers from the Company regarding the Company’s and its Subsidiaries’ business, management and financial affairs and the terms and conditions of this Agreement and the Securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Investor or to which Investor had access.

(f)           Reliance on Exemption from Registration.  Investor understands that the Securities have not been under the Act or any applicable state securities laws and that the sale contemplated hereby is being made in reliance on an exemption from registration therefrom.

(g)          Short Sales.  Neither Investor nor any of its affiliates has, will, or will cause any person to directly engage in “short sales” of the Company’s Common Stock during the term of this Agreement or during the 60 days immediately preceding the Effective Date.

(h)          Patriot Act and Money Laundering.  Investor certifies that, to the best of Investor’s knowledge, Investor has not been designated, and is not owned or controlled, by a “suspected terrorist” as defined in Executive Order 13224.  Investor hereby represents, warrants and covenants that:  (i) none of the cash or property that Investor will invest pursuant to this Agreement has been or shall be derived from, or related to, any activity that is deemed criminal under United States law; and (ii) no

 

17

  

  

  

 

disbursement by Investor to the Company to the extent within Investor’s control, shall cause Investor to be in violation of the United States Bank Secrecy Act, the United States International Money Laundering Control Act of 1986 or the United States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001.  Investor shall promptly notify the Company if any of these representations ceases to be true and accurate regarding Investor.  Investor agrees to provide the Company any additional information regarding Investor that the Company deems necessary or convenient to ensure compliance with all applicable laws concerning money laundering and similar activities.  Investor understands and agrees that if at any time it is discovered that any of the foregoing representations are incorrect, or if otherwise required by applicable law or regulation related to money laundering similar activities, the Company may undertake appropriate actions to ensure compliance with applicable law or regulation, including but not limited to segregation and/or redemption of Investor’s investment in the Company.  Investor further understands that the Company may release information about Investor and, if applicable, any underlying beneficial owners, to proper authorities if the Company, in its sole discretion, determines that it is in the best interests of the Company in light of relevant rules and regulations under the laws set forth in subsection (ii) above.

 

The Company acknowledges and agrees that Investor does not make or has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Section 4.2.

 

 

ARTICLE 5

OTHER AGREEMENTS OF THE PARTIES

 

5.1           Transfer Restrictions

(a)          The Securities may only be disposed of in compliance with state and federal securities laws.  In connection with any transfer of Securities other than (i) pursuant to an effective Registration Statement or Rule 144, (ii) to the Company, (iii) to an Affiliate of Investor, or (iv) in connection with a pledge as contemplated in Section 5.1(b), the Company may require the transferor thereof to provide to the Company an opinion of Borteck, Sanders & Torzewski, LLP (“Borteck”), or other counsel selected by the transferor and reasonably acceptable to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Act.

 

(b)          Investor agrees to the imprinting, so long as is required by this Section 5.1, of the following legend, or substantially similar legend, on any certificate evidencing Securities:

NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

The Company agrees to cause such legend to be removed immediately upon effectiveness of a Registration Statement, or when any Common Shares are eligible for sale under Rule 144.  Company further acknowledges and agrees that Investor may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Act and who agrees to be bound by the provisions of this Agreement and, if required under the terms of such arrangement, Investor may transfer pledged or secured Securities to the pledgees or

 

18

  

  

  

 

secured parties.  Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith.  Further, no notice shall be required of such pledge.  At Investor’s reasonable expense, the Company will execute and deliver such documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities.

 

5.2           Furnishing of Information.  As long as Investor owns Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the Effective Date pursuant to the Exchange Act.  Upon the request of Investor, the Company shall deliver to Investor a written certification of a duly authorized officer as to whether it has complied with the preceding sentence.  As long as Investor owns Securities, if the Company is not required to file reports pursuant to such laws, it will prepare and furnish to Investor and make publicly available in accordance with Rule 144(c) such information as is required for Investor to sell the Securities under Rule 144.  The Company further covenants that it will take such further action as any holder of Securities may reasonably request, all to the extent required from time to time to enable such Person to sell such Securities without registration under the Act within the limitation of the exemptions provided by Rule 144.

 

5.3           Integration.  The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Act of the sale of the Securities to Investor or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

5.4           Securities Laws Disclosure; Publicity.  The Company shall timely file a Current Report on Form 8-K as required by this Agreement, and in the Company’s discretion shall file a press release, in each case reasonably acceptable to Investor, disclosing the material terms of the transactions contemplated hereby.  The Company and Investor shall consult with each other in issuing any press releases with respect to the transactions contemplated hereby, and neither the Company nor Investor shall issue any such press release or otherwise make any such public statement without the prior consent of the Company, with respect to any such press release of Investor, or without the prior consent of Investor, with respect to any such press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law or Trading Market regulations, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.  Notwithstanding the foregoing, the Company shall not publicly disclose the name of Investor, or include the name of Investor in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of Investor, except (i) as contained in the Current Report on Form 8-K and press release described above, (ii) as required by federal securities law in connection with any registration statement under which the Common Shares are registered, (iii) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide Investor with prior notice of such disclosure, or (iv) to the extent such disclosure is required in any SEC Report filed by the Company.

 

5.5           Shareholders Rights Plan.  No claim will be made or enforced by the Company or, to the knowledge of the Company, any other Person that Investor is an “Acquiring Person” under any shareholders rights plan or similar plan or arrangement in effect or hereafter adopted by the Company, or that Investor could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and Investor.  The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act of 1940, as amended.

 

5.6           Non-Public Information.  The Company covenants and agrees that neither it nor any other Person acting on its behalf will provide Investor or its agents or counsel with any information that the Company believes or reasonably should believe constitutes material non-public information, unless prior thereto Investor shall have executed a written agreement regarding the confidentiality and use of such information.  On and after the Effective Date, neither Investor nor any Affiliate Investor shall have any duty of trust or

 

19

  

  

  

 

confidence that is owed directly, indirectly, or derivatively, to the Company or the shareholders of the Company, or to any other Person who is the source of material non-public information regarding the Company.  The Company understands and confirms that Investor shall be relying on the foregoing in effecting transactions in securities of the Company.

5.7           Reimbursement.  If Investor becomes involved in any capacity in any proceeding by or against any Person who is a stockholder of the Company (except as a result of sales, pledges, margin sales and similar transactions by Investor to or with any current stockholder), solely as a result of Investor’s acquisition of the Securities under this Agreement, the Company will reimburse Investor for its reasonable legal and other expenses (including the cost of any investigation preparation and travel in connection therewith) incurred in connection therewith, as such expenses are incurred, or will assume the defense of Investor in such matter.  The reimbursement obligations of the Company under this Section 5.7 shall be in addition to any liability which the Company may otherwise have, shall extend upon the same terms and conditions to any Affiliates of Investor who are actually named in such action, proceeding or investigation, and partners, directors, agents, employees and controlling persons (if any), as the case may be, of Investor and any such Affiliate, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, Investor and any such Affiliate and any such Person.  The Company also agrees that neither Investor nor any such Affiliates, partners, directors, agents, employees or controlling persons shall have any liability to the Company or any Person asserting claims on behalf of or in right of the Company solely as a result of acquiring the Securities under this Agreement.

 

5.8           Indemnification

 

(a)          Company Indemnification Obligation.  Subject to the provisions of this Section 5.8, the Company will indemnify and hold Investor and any Warrant holder, their Affiliates and attorneys, and each of their directors, officers, shareholders, partners, employees, agents, and any person who controls Investor within the meaning of Section 15 of the Act or Section 20 of the Exchange Act (collectively, the “Investor Parties” and each an “Investor Party”), harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation (collectively, “Losses”) that any Investor Party may suffer or incur as a result of or relating to (i) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, (ii) any action instituted against any Investor Party, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of an Investor Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of Investor’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings Investor may have with any such stockholder or any violations by Investor of state or federal securities laws or any conduct by Investor which constitutes fraud, gross negligence, willful misconduct or malfeasance), (iii)  any untrue statement or alleged untrue statement of a material fact contained in a Registration Statement (or in a Registration Statement as amended by any post-effective amendment thereof by the Company) or arising out of or based upon any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and/or (iv) any untrue statement or alleged untrue statement of a material fact included in any Prospectus ( or any amendments or supplements to any Prospectus ), in any free writing prospectus, in any “issuer information” (as defined in Rule 433 under the Act) of the Company, or in any Prospectus together with any combination of one or more of the  free writing prospectuses, if any, or arising out of or based upon any omission or alleged omission to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(b)          Investor Indemnification Obligation.  Subject to the provisions of this Section 5.8, Investor will indemnify and hold the Company, its Affiliates and attorneys, and each of their directors, officers, shareholders, partners, employees, agents, and any person who controls Investor within the meaning of Section 15 of the Act or Section 20 of the Exchange Act (collectively, the “Company Parties” and each a “Company Party”), harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation (collectively, “Losses”) that any Company Party may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by Investor in this Agreement or in the other Transaction Documents.

 

20

  

  

  

 

(c)          Indemnification Procedures.  If any action shall be brought against an Investor Party or a Company Party (an “Indemnified Party”) in respect of which indemnity may be sought pursuant to this Agreement, such Indemnified Party shall promptly notify the party required to provide indemnification (the “Indemnitor”) in writing, and the Indemnitor shall have the right to assume the defense thereof with counsel of its own choosing.  The Indemnified Parties shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of the Indemnified Parties except to the extent that (i) the employment thereof has been specifically authorized by the Indemnified Party in writing, (ii) the Indemnitor has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict with respect to the dispute in question on any material issue between the position of the Indemnified Party and the position of the Indemnitor such that it would be inappropriate for one counsel to represent the Indemnified Party and the Indemnitor.  The Indemnitor will not be liable to the Indemnified Party under this Agreement (i) for any settlement by an Indemnified Party effected without the Indemnitor’s prior written consent, which shall not be unreasonably withheld or delayed; or (ii) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to the Indemnified Party’s breach of any of the representations, warranties, covenants or agreements made by the Indemnified Party in this Agreement or in the other Transaction Documents.

5.9           Reservation of Securities.  The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents in such amount as may be required to fulfill its obligations in full under the Transaction Documents.

 

5.10         Limited Standstill.  The Company will deliver to Investor on or before each Tranche Closing Date, and will honor and enforce, and will take reasonable actions to assist Investor in enforcing, the provisions of, the Lock-Up Agreements with the Company’s officers, directors and beneficial owners of 10% or more of the Common Stock.

 

5.11         Prospectus Availability and Changes.  The Company will make available to Investor upon request, and thereafter from time to time will furnish Investor, as many copies of any Prospectus (or of the Prospectus as amended or supplemented if the Company shall have made any amendments or supplements thereto after the effective date of the applicable Registration Statement) as Investor may request for the purposes contemplated by the Act; and in case Investor is required to deliver  a prospectus after the nine-month period referred to in Section 10(a)(3) of the Act in connection with the sale of the Common Shares, or after the time a post-effective amendment to the applicable Registration Statement is required pursuant to Item 512(a) of Regulation S-K under the Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Act or Item 512(a) of Regulation S-K under the Act, as the case may be.

 

The Company will advise Investor promptly of the happening of any event within the time during which a Prospectus is required to be delivered under the Act which could require the making of any change in the Prospectus then being used so that the Prospectus would not include an untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading, and to advise Investor promptly if, during such period, it shall become necessary to amend or supplement any Prospectus to cause such Prospectus to comply with the requirements of the Act, and in each case, during such time, to prepare and furnish, at the Company’s expense, to Investor promptly such amendments or supplements to such Prospectus as may be necessary to reflect any such change or to effect such compliance.

5.12         Required Approval.  No transactions contemplated under this Agreement or the Transaction Documents shall be consummated for an amount that would require approval by any Trading Market or Company stockholders under any approval provisions, rules or regulations of any Trading Market applicable to the Company, unless and until such approval is obtained.  Company shall use best efforts to obtain any required approval as soon as possible.

 

5.13         Activity Restrictions.  For so long as Investor or any of its Affiliates holds any Preferred Shares, Warrant, or Warrant Shares, neither Investor nor any Affiliate will: (i) vote any shares of Common Stock owned or controlled by it, solicit any proxies, or seek to advise or influence any Person with respect to any voting securities of the Company; (ii) engage or participate in any actions, plans or proposals which relate to or would result in (a) acquiring additional securities of the Company, alone or together with any other Person,

 

21

  

  

  

 

which would result in beneficially owning or controlling more than 9.99% of the total outstanding Common Stock or other voting securities of the Company, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Company or any of its subsidiaries, (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries, (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the present capitalization or dividend policy of the Company, (f) any other material change in the Company’s business or corporate structure, including but not limited to, if the Company is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940, (g) changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any Person, (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant  to Section 12(g)(4) of the Act, or (j) any action, intention, plan or arrangement similar to any of those enumerated above; or (iii) request the Company or its directors, officers, employees, agents or representatives to amend or waive any provision of this Section 5.13.

 

5.14         Registration Statements and Prospectuses.

 

(a)          The Company will use its best efforts to file within 45 calendar days after the Effective Date (or as soon as possible thereafter), to cause to become effective as soon as possible thereafter, and to remain effective until all Common Shares have been sold or are Rule 144 Eligible, a Registration Statement for the resale of all Common Shares issued hereunder (including without limitation all Warrant Shares underlying the Warrant).  Each Registration Statement shall comply when it becomes effective, and, as amended or supplemented, at the time of any Tranche Notice Date, Tranche Closing Date, or issuance of any Common Shares, and at all times during which a prospectus is required by the Act to be delivered in connection with any sale of Common Shares, will comply, in all material respects, with the requirements of the Act.

 

(b)          Each Registration Statement, as of its respective effective time, will not, as applicable, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

(c)          Each Prospectus will comply, as of its date and the date it will be filed with the SEC, and, at the time of any Tranche Notice Date, Tranche Closing Date, or issuance of any Common Shares, and at all times during which a prospectus is required by the Act to be delivered in connection with any sale of Common Shares, will comply, in all material respects, with the requirements of the Act.

 

(d)          At no time during the period that begins on the date a Prospectus is filed with the SEC and ends at the time a Prospectus is no longer required by the Act to be delivered in connection with any sale of Common Shares will any such Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(e)          Each Registration Statement will meet, and the offering and sale of the Common Shares as contemplated hereby will comply with, the requirements of Rule 415 under the Act.

 

(f)          The Company will not, directly or indirectly, use or refer to any “free writing prospectus” (as defined in Rule 405 under the Act) except in compliance with Rules 164 and 433 under the Act.

 

5.15         Investor Due Diligence.  Investor shall have the right and opportunity to conduct due diligence, at its own expense, with respect to any Registration Statement or Prospectus in which the name of Investor or any Affiliate of Investor appears.

22 

  

  

  

 

ARTICLE 6

MISCELLANEOUS

 

6.1           Fees and Expenses.  Except for the $15,000.00 non-refundable document preparation fee previously paid by the Company to counsel for Investor, the receipt of which is hereby acknowledged, or as may be otherwise provided in this Agreement, each party shall pay the fees and expenses of its own advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of the Transaction Documents.  The Company acknowledges and agrees that Borteck Sanders & Torzewski, LLP, solely represents Investor, and does not represent the Company or its interests in connection with the Transaction Documents or the transactions contemplated thereby.  The Company shall pay all stamp and other taxes and duties levied in connection with the sale of the Securities, if any.

6.2           Notices.  Unless a different time of day or method of delivery is set forth in the Transaction Documents, any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of:  (a) the date of transmission, if such notice or communication is delivered via facsimile or electronic mail prior to 5:30 p.m. Eastern time on a Trading Day and an electronic confirmation of delivery is received by the sender, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered later than 5:30 p.m. Eastern time or on a day that is not a Trading Day, (c) three Trading Days following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given.  The addresses for such notices and communications are those set forth following the signature page hereof, or such other address as may be designated in writing hereafter, in the same manner, by such Person.

 

6.3           Amendments; Waivers.  No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and Investor or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

6.4           Headings.  The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof

 

6.5           Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.  The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Investor, which consent shall not be unreasonably withheld or delayed.  Investor may assign any or all of its rights under this Agreement (a) to any Affiliate, or (b) to any Person to whom Investor assigns or transfers any Securities.

 

6.6           No Third-Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 5.8.

 6.7          Governing Law; Dispute Resolution.  All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the laws of the State of New York, without regard to the principles of conflicts of law that would require or permit the application of the laws of any other jurisdiction.  Any controversy, claim or dispute arising out of or relating to this Agreement, or the making, performance or interpretation thereof, including, without limitation, the interpretation and scope of this arbitration provision, whether in contract, in tort or otherwise, shall be settled by final and binding arbitration under the auspices of the American Arbitration Association ("AAA") in New York City, New York in accordance with the expedited dispute of resolution procedures and the commercial arbitration rules of the AAA then in effect.  Any arbitration conducted pursuant to this Section 18 shall be chosen by the parties from lists of qualified arbitrators submitted by the AAA.  The determination the arbitrator in the arbitration shall be conclusive and binding on the parties hereto and shall not be subject to appeal or judicial review.  The award of the

 

23

  

  

  

 

arbitrator may be enforced in any court of competent jurisdiction and each of the parties hereby unconditionally and irrevocably consents to the jurisdiction of the state and federal courts located in the State of New York solely with respect to (and for no reason or other purpose) any action instituted to enforce any such award.  The award of the arbitrators may also be enforced in any other court of competent jurisdiction.  Each of the parties unconditionally and irrevocably waives any right to a trial by jury in respect of any such action.  The arbitrator shall be entitled to award and apportion the costs and expenses of the parties in connection with any arbitration (including, without limitation, attorneys fees and expenses) as the arbitrators, in their discretion, may determine.

6.8           Survival.  The representations and warranties contained herein shall survive the Closing and the delivery and exercise of the Securities.

 

6.9           Execution.  This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof.

 

6.10         Severability.  If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

6.11         Replacement of Securities.  If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested.  The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities.

 

6.12         Remedies.  In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of Investor and the Company will be entitled to specific performance under the Transaction Documents.  The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.

6.13         Payment Set Aside.  To the extent that the Company makes a payment or payments to Investor pursuant to any Transaction Document or Investor enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.14         Time of the Essence.  Time is of the essence with respect to all provisions of this Agreement that specify a time for performance.

6.15         Construction.  The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

6.16         Entire Agreement.  This Agreement, together with the Exhibits, Appendices and Schedules hereto, contains the entire agreement and understanding of the parties, and supersedes all prior and contemporaneous agreements, term sheets, letters, discussions, communications and understandings, both oral and written, which the parties acknowledge

 

24

  

  

  

 

have been merged into this Agreement.  No party, representative, attorney or agent has relied upon any collateral contract, agreement, assurance, promise, understanding or representation not expressly set forth hereinabove.  The parties hereby expressly waive all rights and remedies, at law and in equity, directly or indirectly arising out of or relating to, or which may arise as a result of, any Person’s reliance on any such assurance.

6.17         Addresses for Notice.  Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given, (i) on the date received, (a) by personal delivery, or (b) if advance copy is given by fax, (ii) seven (7) Business Days after deposit with the applicable government postal service by certified mail, or (iii) three (3) Business Days mailing by reputable international express courier, with postage and fees prepaid, addressed to each of the other parties thereunto entitled at the following addresses, or at such other addresses as a party may designate by fifteen (15) days advance written notice to each of the other parties hereto.

If to the Company:

Revonergy Inc.

Landmark House

17 Hanover Square

London UK  W1S 1HU

If to the Investor:

 

 

Kodiak Capital Group, LLC

One Columbus Place, 25th Floor

New York, NY 10019

Fax No.:  (212) 262-2601

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

REVONERGY INC.

 

 

/s/ Ravi Daswani

Ravi Daswani, President & CEO

KODIAK CAPITAL GROUP, LLC

/s/ Ryan C. Hodson

25

  

  

  

EXHIBIT A

FORM OF WARRANT

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

 

Revonergy Inc.

 

 

Warrant To Purchase Common Stock

	
Warrant No.: 2010-1

	
Issuance Date:   [__], 2010

Number of Warrant Shares:  [____________]

Initial Exercise Price:  $[____] per share

Revonergy Inc., a Nevada corporation (“Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Kodiak Capital Group, LLC, a Delaware limited liability company, the holder hereof or its designees or assigns (“Holder”), is entitled, subject to the terms set forth herein, to purchase from the Company, at the Exercise Price then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrant to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times after issuance of the Warrant and until 11:59 p.m. Eastern time on the fifth anniversary of the Tranche Notice Date for each applicable Warrant Tranche, subject to acceleration pursuant to Section 3.3 hereof, that number of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock set forth above and as adjusted herein (the “Warrant Shares”); provided, however, that this Warrant may only be exercised, from time to time, for that number of shares of Common Stock equal to 135% of the cumulative amount of Tranche Purchase Prices under Tranche Notices delivered prior to or on the date of exercise.  Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in ARTICLE 13 hereof.

 

 

This Warrant is issued pursuant to the Preferred Stock Purchase Agreement dated September 1, 2010, by and among the Company and the investor referred to therein (the “Purchase Agreement”).

This Warrant shall consist of and be exercisable in tranches (each, a “Warrant Tranche”), with a separate tranche being created upon each delivery of a Tranche Notice under the Purchase Agreement.  Each Warrant Tranche will grant to the Holder the right, for a five-year period commencing on the applicable Tranche Notice Date, to exercise the Warrant and purchase up to a number of shares of Common Stock with an Aggregate Exercise Price equal to 135% of the Tranche Purchase Price for the applicable Tranche Notice.  Attached to this Warrant is a schedule (the “Warrant Tranche Schedule”) that sets forth the issuance date, the number of Warrant Shares, and the Exercise Price for each Warrant Tranche.  The Warrant Tranche Schedule shall be updated by the Company, with an updated copy provided to the Holder, promptly following each exercise of this Warrant.  No portion of this Warrant shall vest or be exercisable except under the Warrant Tranches.

 

A-1

  

  

  

 

ARTICLE 1

EXERCISE OF WARRANT

 

 

1.1           Mechanics of Exercise.

 

 

1.1.1       Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder on any day on or after the Issuance Date, in whole or in part, by (i) delivery of a written notice to the Company, in the form attached hereto as Appendix 1 (the “Exercise Notice”), of the Holder’s election to exercise this Warrant, and (ii) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”), with such payment made, at Investor’s option, (x) in cash or by wire transfer of immediately available funds, or (y) by cashless exercise pursuant to Section 1.3.

 

1.1.2       The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder.  Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.

 

1.1.3       On the Trading Day on which the Company has received each of the Exercise Notice and the Aggregate Exercise Price (the “Exercise Delivery Documents”) from the Holder by 6:30 p.m. Eastern time, or on the next Trading Day if the Exercise Delivery Documents are received after 6:30 p.m. Eastern time or on a non-Trading Day (in each case, the “Exercise Delivery Date”), the Company shall transmit (i) a facsimile acknowledgment of confirmation of receipt of the Exercise Delivery Documents to the Holder, and (ii) an electronic copy of its share issuance instructions to the Holder and to the Company’s transfer agent (the “Transfer Agent”), with such transmissions to comply with the notice provisions contained in Section 6.2 of the Purchase Agreement, and shall instruct and authorize the Transfer Agent to issue such aggregate number of Warrant Shares that the Holder is entitled to receive upon such exercise to the Holder or its designee.

1.1.4       Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are issued.  Any Warrant delivered in connection with a Tranche Notice and exercised by Holder shall be deemed exercised (i) on the Tranche Notice Date, if exercised by 6:30 p.m. Eastern time on the Tranche Notice Date, or (ii) on the next Trading Day, if exercised by Investor after 6:30 p.m. Eastern Time on the Tranche Notice Date or on any other date, in each case with Holder deemed to be a holder of record as of such date.

 

1.1.5       If this Warrant is exercised and the number of Warrant Shares represented by this Warrant is greater than the number of Warrant Shares being acquired upon such exercise, then the Company shall, as soon as practicable and in no event later than one Trading Day after such exercise, update the Tranche Exercise Schedule to reflect the revised number of Warrant Shares for which this Warrant is then exercisable and deliver a copy of the updated Tranche Exercise Schedule to the Holder.  No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number.  The Company shall pay any and all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.

 

1.2           Adjustments to Exercise Price and Number of Shares.  In addition to other adjustments specified herein, the Exercise Price of this Warrant and the number of shares of Common Stock issuable upon exercise shall be adjusted as follows:

 

1.2.1       Exercise Price.  The “Exercise Price” per share of Common Stock underlying this Warrant, subject to further adjustment as provided herein, shall be as follows: (i) with respect to the portion of this Warrant issued on the Effective Date and until the first Tranche Notice Date, the amount per Warrant Share set forth on the face of this

 

A-2

  

  

  

 

Warrant, which is equal to Closing Bid Price for the Common Stock on the Trading Day prior to the Effective Date, and (ii) with respect to the portion of this Warrant that becomes exercisable on any Tranche Notice Date (including the first Tranche Notice Date), an amount per Warrant Share equal to the Closing Bid Price of a share of Common Stock on such Tranche Notice Date.

1.2.2       Number of Shares.  The number of Warrant Shares underlying this Warrant and each Warrant Tranche, subject to further adjustment as provided herein, shall be as follows: (i) with respect to the portion of this Warrant issued on the Effective Date and until the first Tranche Notice Date, the number of shares set forth on the face of this Warrant, which is a number of shares of Common Stock equal to the Maximum Placement multiplied by 135%, with the resulting sum divided by the Closing Bid Price of a share of Common Stock on the Trading Day prior to the Effective Date, and (ii) with respect to the portion of this Warrant issued on any Tranche Notice Date including the first Tranche Notice Date, a number of shares equal to the Tranche Purchase Price set forth in the applicable Tranche Notice multiplied by 135%, with the resulting sum divided by the Closing Bid Price of a share of Common Stock on the Tranche Notice Date.  For example, if the Tranche Purchase Price is $500,000 and the Closing Bid Price is $1.00, then the number of Warrant Shares underlying that Warrant Tranche shall be $500,000 x 135% = $675,000 divided by $1.00 = 675,000 shares of Common Stock.  On each Tranche Notice Date, the number of Warrant Shares underlying the related Warrant Tranche shall vest and become exercisable, and the aggregate number of Warrant Shares underlying this Warrant that are currently exercisable shall automatically adjust up or down to account for the change in the number of Warrant Shares covered by the new Warrant Tranche and for any Warrant Shares issued upon any prior or simultaneous exercise of this Warrant.  If at any time the Holder reasonably believes that the number of Warrant Shares included in the Registration Statement is not sufficient to cover all exercises under this Warrant, then the Company shall amend such Registration Statement to include the additional number of Warrant Shares that may be required to provide such coverage.

 

1.3           Cashless Exercise.  Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the following formula (a “Cashless Exercise”):

 

 

	
Net Number =

	
(B-C) x A

	  	
B

For purposes of the foregoing formula:

A = the total number of shares with respect to which this Warrant is then being exercised.

B = the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg) for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice.

C = the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

1.4           Company’s Failure to Timely Deliver Securities.  Intentionally Omitted.

 

1.5           Exercise Limitation.  In no event shall a Holder be permitted to exercise this Warrant, or part hereof, if, upon such exercise, the number of shares of Common Stock beneficially owned by the Holder (other than shares which would otherwise be deemed beneficially owned except for being subject to a limitation on conversion or exercise analogous to the limitation contained in this Article 1.5), would exceed 9.99% of the number of shares of Common Stock then issued and outstanding.  As used herein, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder.  To the extent that the limitation contained in this Article 1.5 applies, the submission of an Exercise Notice by the Holder shall be deemed to be the Holder’s representation that this Warrant is exercisable pursuant to the terms hereof and the Company shall be entitled to rely on such representation without making any further inquiry as to whether this Article 1.5 applies.  Nothing contained herein shall be deemed to restrict

 

A-3

  

  

  

 

the right of a Holder to exercise this Warrant, or part thereof, at such time as such exercise will not violate the provisions of this Article 1.5.  This Article 1.5 may not be amended unless such amendment is approved by the holders of a majority of the Common Stock then outstanding; provided, however, that the limitations contained in this Article 1.5 shall cease to apply upon sixty (60) days’ prior written notice from the Holder to the Company.

1.6           Activity Restrictions.  For so long as Holder or any of its affiliates holds this Warrant or any Warrant Shares, neither Holder nor any affiliate will:  (i) vote any shares of Common Stock owned or controlled by it, solicit any proxies, or seek to advise or influence any Person with respect to any voting securities of the Company; (ii) engage or participate in any actions, plans or proposals which relate to or would result in (a) acquiring additional securities of the Company, alone or together with any other Person, which would result in beneficially owning or controlling more than 9.99% of the total outstanding Common Stock or other voting securities of the Company, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Company or any of its subsidiaries, (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries, (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the present capitalization or dividend policy of the Company, (f) any other material change in the Company’s business or corporate structure, including but not limited to, if the Company is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940, (g) changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any Person, (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant  to Section 12(g)(4) of the Act, or (j) any action, intention, plan or arrangement similar to any of those enumerated above; or (iii) request the Company or its directors, officers, employees, agents or representatives to amend or waive any provision of this Section 1.6.

 

1.7           Disputes.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.

 

1.8           Insufficient Authorized Shares.  If at any time while any portion of this Warrant remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least a number of shares of Common Stock equal to 110% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the portion of the Warrant then outstanding (the “Required Reserve Amount”) (an “Authorized Share Failure”), then the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the portion of the Warrant then outstanding.  Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than 90 days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock.  In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal.

ARTICLE 2

ADJUSTMENT UPON SUBDIVISION OR COMBINATION OF COMMON STOCK

 

 

If the Company at any time on or after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased.  If the Company at any time on or after the Issuance Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the

 

A-4

  

  

  

 

number of Warrant Shares will be proportionately decreased.  Any adjustment under this ARTICLE 2 shall become effective at the close of business on the date the subdivision or combination becomes effective.

 

 

ARTICLE 3

PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS

 

 

3.1           Purchase Rights.  In addition to any adjustments pursuant to ARTICLE 2 above, if at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.

3.2           Subsequent Equity Sales.  In addition to any adjustments made pursuant to ARTICLE 2 above, if the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock, at an effective price per share less than the then Exercise Price (such lower price, the “Base Share Price” and such issuances, collectively, a “Dilutive Issuance”), then the Exercise Price shall be reduced and only reduced to equal the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment.  Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  If the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share which is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance.  Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 3.2 in respect of an Exempt Issuance, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of the Purchase Agreement.  The Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 3.2, indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice the “Dilutive Issuance Notice”).  For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 3.2, upon the occurrence of any Dilutive Issuance, after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant Shares based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise.

 

3.3           Fundamental Transactions.  The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity assumes in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3.3 pursuant to written agreements in form and substance satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each Holder of this Warrant in exchange for such Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and satisfactory to the Required Holders.  Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been

 

A-5

  

  

  

 

named as the Company herein.  Upon consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been converted immediately prior to such Fundamental Transaction, as adjusted in accordance with the provisions of this Warrant.  In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been exercised immediately prior to such Fundamental Transaction; provided, however, that in the event the Fundamental Transaction involves the issuance of cash or freely tradable securities by an issuer listed on the New York Stock Exchange or the Nasdaq Stock Market, then the ability to exercise this Warrant shall expire on the consummation of that Fundamental Transaction.  Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Required Holders.  The provisions of this Section 3.3  shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant.

3.4           Purchase of Warrant.  Notwithstanding the foregoing Section 3.3, in the event of a Fundamental Transaction other than one in which the Successor Entity is a Public Successor Entity that assumes this Warrant such that this Warrant shall be exercisable for the publicly traded common stock of such Public Successor Entity, at the request of the Holder delivered before the 90th day after the effective date of such Fundamental Transaction, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Trading Days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the value of the remaining unexercised portion of this Warrant on the date of such consummation, which value shall be determined by use of the Black Schools Option Pricing Model using a volatility equal to the 100 day average historical price volatility prior to the date of the public announcement of such Fundamental Transaction.

ARTICLE 4

NONCIRCUMVENTION

 

 

The Company hereby covenants and agrees that the Company will not, by amendment of its certificate or articles of incorporation, articles of association, bylaws, or any other organization documents, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.  Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any portion of this Warrant remains outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of this Warrant, 110% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of this Warrant then outstanding (without regard to any limitations on exercise).

 

A-6

  

  

  

 

ARTICLE 5

WARRANT HOLDER NOT DEEMED A STOCKHOLDER

 

 

Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.  In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.  Notwithstanding this ARTICLE 5, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.

 

 

ARTICLE 6

REISSUANCE OF WARRANTS

 

 

6.1           Transfer of Warrant.  If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 6.4), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 6.4) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

 

6.2           Lost, Stolen or Mutilated Warrant.  Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 6.4) representing the right to purchase the Warrant Shares then underlying this Warrant.

6.3           Exchangeable for Multiple Warrant.  This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 6.4) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrant for fractional shares of Common Stock shall be given.

 

6.4           Issuance of New Warrant.  Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 6.1 or Section 6.3, the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrant issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

 

 

ARTICLE 7

NOTICES

 

 

Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 6.2 of the Purchase Agreement.  The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefore.  Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price,

 

A-7

  

  

  

 

 setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock as such or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

 

ARTICLE 8

AMENDMENT AND WAIVER

 

 

Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders; provided that except as set forth in this Warrant no such action may increase the exercise price of any Warrant or decrease the number of shares or class of stock obtainable upon exercise of any Warrant without the written consent of the Holder.  No such amendment shall be effective to the extent that it applies to less than all of the holders of this Warrant.

 

 

ARTICLE 9

GOVERNING LAW

 

 

This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

 

 

ARTICLE 10

CONSTRUCTION; HEADINGS

 

 

This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any person as the drafter hereof.  The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.

 

 

ARTICLE 11

DISPUTE RESOLUTION

 

 

In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within 2 Trading Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder.  If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three Trading Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within 2 Trading Days submit via facsimile (a) the disputed determination of the Exercise Price or arithmetic calculation to an independent, reputable investment bank or independent registered public accounting firm selected by Holder subject to Company’s approval, which may not be unreasonably withheld or delayed, or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent registered public accounting firm.  The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than 3 Trading Days from the time it receives the disputed determinations or calculations.  Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.

 

A-8

  

  

  

 

ARTICLE 12

REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF

 

 

The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder right to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.  The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

 

 

ARTICLE 13

DEFINITIONS

 

 

For purposes of this Warrant, in addition to the terms defined elsewhere herein, the following terms shall have the following meanings:

 

 

13.1         “Bloomberg” means Bloomberg Financial Markets.

 

 

13.2         “Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Trading Market, as reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00 p.m., Eastern time, as reported by Bloomberg, or, if the Trading Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.).  If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and Holder.  If the Company and Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to ARTICLE 11.  All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

13.3         “Common Stock” means (i) the Company’s shares of Common Stock, par value $0.001 per share, and (ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.

 

13.4         “Common Stock Deemed Outstanding” means, at any given time, the number of shares of Common Stock actually outstanding at such time, plus the number of shares of Common Stock deemed to be outstanding pursuant to Section 3.1 hereof regardless of whether the Options or Convertible Securities are actually exercisable at such time, but excluding any shares of Common Stock owned or held by or for the account of the Company or issuable upon exercise of this Warrant.

 

13.5         “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

13.6         “Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.

 

A-9

  

  

  

 

13.7         “Eligible Market” means the Trading Market, The New York Stock Exchange, Inc., The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market, the NYSE Amex or the OTC Bulletin Board, but does not include the Pink Sheets.

 

13.8         “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers, directors or consultants of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except as a result of anti-dilution provisions therein), and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

 

13.9         “Fundamental Transaction” has the meaning set forth in the Purchase Agreement.

 

13.10       “Maximum Placement” has the meaning set forth in the Purchase Agreement.

 

13.11       “Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

13.12       “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

 

13.13       “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

 

13.14       “Public Successor Entity” means a Successor Entity that is a publicly traded corporation whose stock is quoted or listed for trading on an Eligible Market.

 

13.15       “Required Holders” means the Holders of this Warrant representing at least a majority of shares of Common Stock underlying this Warrant as then outstanding.

 

13.16       “Successor Entity” means the Person (or, if so elected by the Required Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into.

 

13.17       “Trading Day” means any day on which the Common Stock is traded on an Eligible Market; provided that it shall not include any day on which the Common Stock (a) is suspended from trading, or (b) is scheduled to trade on such exchange or market for less than 5 hours.

 

13.18       “Trading Market” means the OTC Bulletin Board, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE Amex, or the New York Stock Exchange, whichever is at the time the principal trading exchange or market for the Common Stock, but does not include the Pink Sheets inter-dealer electronic quotation and trading system.

 

13.19       “Tranche Closing Date” has the meaning set forth in the Purchase Agreement.

 

A-10

  

  

  

 

13.20       “Tranche Notice” has the meaning set forth in the Purchase Agreement.

 

13.21       “Tranche Notice Date” has the meaning set forth in the Purchase Agreement.

 

13.22       “Tranche Purchase Price” has the meaning set forth in the Purchase Agreement.

 

IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

 

 

REVONERGY INC.

 

 

By:                                                                

Name:                                                                

Title:                                                                

 

 

 

Warrant Exercise Schedule

 

 

	
Exercise Date

	
Number of

Warrant Shares

	
Exercise Price

Per Share

	
Aggregate Exercise

Price

	
Dollar Amount

Remaining

	  	  	  	  	  

A-11

  

  

  

APPENDIX 1

 

 

EXERCISE NOTICE

 

 

REVONERGY INC.

 

 

The undersigned hereby exercises the right to purchase ________________ shares of Common Stock (“Warrant Shares”) of Revonergy Inc., a Nevada corporation (“Company”), evidenced by the attached Warrant to Purchase Common Stock (“Warrant”).  Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.  The Holder intends that payment of the Exercise Price shall be made as:

 

 

	
___

	
Cash Exercise with respect to ____________ Warrant Shares

	  	  
	
___

	
Cashless Exercise with respect to ____________ Warrant Shares

Please issue _________________________ a certificate or certificates representing said shares of Common Stock in the name specified below

	
___

	
Said shares in electronic form to the Deposit/Withdrawal at Custodian (DWAC) account with Depository Trust Company (DTC) specified below.

	  
	
By:

	
Name:

	
Title:

 

 

 

ACKNOWLEDGMENT

 

 

The Company hereby acknowledges the foregoing Exercise Notice and hereby directs Empire Stock Transfer Inc. to issue the above indicated number of shares of Common Stock according to the instructions to be provided separately.

 

 

REVONERGY INC.

 

 

By:                                                                

Name:                                                                

Title:                                                                

 

 

A-12

  

  

  

EXHIBIT B

REVONERGY INC.

DESIGNATION OF RIGHTS, PRIVILEGES, AND PREFERENCES OF

SERIES A REDEEMABLE PREFERRED STOCK

Pursuant to the provisions of Nevada Revised Statutes, §§ 78.195 and 78.1955, the undersigned corporation, Revonergy Inc. (the “Corporation”), hereby adopts the following Designation of Rights, Privileges, and Preferences of Series A Redeemable Preferred Stock (the “Designation”):

FIRST:  The name of the Corporation is Revonergy Inc.

SECOND:  The following resolution establishing a series of preferred stock designated as the “Series A Redeemable Preferred Stock,” consisting of 50,000 shares, par value $0.001, was duly adopted by the board of directors of the Corporation effective as of September 7, 2010, in accordance with the articles of incorporation of the Corporation and the corporation laws of the state of Nevada:

RESOLVED, there is hereby created a series of preferred stock of the Corporation to be designated as the “Series A Redeemable Preferred Stock,” consisting of 50,000 shares, par value $0.001 (referred to herein as the “Preferred Stock”), with the following powers, preferences, rights, qualifications, limitations, and restrictions:

1.           Liquidation.

1.01        In the event of any voluntary or involuntary liquidation (whether complete or partial), dissolution, or winding up of the Corporation, the holders of the Preferred Stock shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, whether from capital, surplus, or earnings, an amount per share in cash equal to the original issuance price per share, plus all accumulated but unpaid dividends, subject to the priority distribution required respecting any issued and outstanding shares of any series of preferred stock authorized prior to the date hereof.  No distribution shall be made on any common stock or other subsequent series of preferred stock of the Corporation by reason of any voluntary or involuntary liquidation (whether complete or partial), dissolution, or winding up of the Corporation unless each holder of any Preferred Stock shall have received all amounts to which such holder shall be entitled under this subsection 1.01.

1.02        If on any liquidation (whether complete or partial), dissolution, or winding up of the Corporation, the assets of the Corporation available for distribution to holders of Preferred Stock and any other stock ranking as to any such distribution on a parity with the Preferred Stock shall be insufficient to pay the holders of outstanding Preferred Stock or such other stock the full amounts to which they otherwise would be entitled under subsection 1.01, the assets of the Corporation available for distribution to holders of Preferred Stock or such other stock shall be distributed to them pro rata on the basis of the full respective preferential amounts to which they are entitled.

2.            Voting Rights.  The Preferred Stock shall not be voted on any matter submitted to the stockholders for consideration, except to the extent that the consent of the holders of the Preferred Stock, voting as a class, is specifically required by the provisions of the corporation laws of the state of Nevada, as now existing or as hereafter amended.  Notwithstanding the foregoing, the holders of the Preferred Stock shall vote as a separate class on any resolution proposed for adoption by the stockholders of the Corporation that seeks to: (a) authorize, create, or issue, or increase the authorized or issued amount, of any class or series of stock ranking senior to the Preferred Stock with respect to the payment of dividends or the distribution of assets upon dissolution, liquidation, or winding up of the Corporation or that may be convertible into any class of shares ranking senior to the Preferred Stock as regards to participation in dividends or the distribution of assets on dissolution, liquidation, or winding up; or (b) amend, alter,

 

B-1

  

  

  

 

or repeal the provisions of the Corporation’s articles of incorporation or this Designation, so as to adversely affect any right, preference, privilege, or voting power of the Preferred Stock or the holders thereof.  In addition, without the approval of holders of at least a majority of the issued and outstanding shares of Preferred Stock, the Corporation shall not become subject to any restriction on the Preferred Stock other than restrictions arising under the general corporation laws of the state of Nevada or existing under the articles of incorporation of the Corporation as in effect on the date of this Designation.  When entitled to vote in accordance with the foregoing, each holder of Preferred Stock shall be entitled to one vote for each share of such Preferred Stock.

3.            Dividends.  The holders of the then-outstanding shares of Preferred Stock shall be entitled to receive, in preference to the holders of any other shares of capital stock of the Corporation, cumulative dividends on the original purchase price per share at an annual rate of 15%, when and as if they may be declared by the board of directors out of funds legally available therefor (the “Series A Dividends”).  The Series A Dividends shall accrue on the Preferred Stock commencing on the date of original issuance thereof.  All Series A Dividends shall be cumulative, whether or not earned or declared and whether or not there are profits, surplus, or other funds of the Corporation legally available for the payment of dividends.  Dividends paid on shares of Preferred Stock in an amount less than the total amount of such dividends at the time accumulated and payable on such shares shall be allocated pro rata on a share-by-share basis among all such shares at the time outstanding.  Unless full cumulative dividends on the Preferred Stock have been paid, or declared and sums set aside for the payment thereof, dividends, other than in common stock, $.001 par value per share (“Common Stock”), or other securities of a class or series of stock of the Corporation the terms of which do not expressly provide that it ranks senior to or on a parity with the Preferred Stock as to dividend distributions and distributions upon the liquidation, winding-up, and dissolution of the Corporation, may not be paid, or declared and sums set aside for payment thereof, and other distributions may not be made upon the Common Stock or other shares of capital stock of the Corporation.

4.           Redemption.

4.01        Subject to the requirements and limitations of the corporation laws of the state of Nevada, the Corporation shall have the right to redeem shares of Preferred Stock on the terms and conditions provided in this section 4.

4.02        Shares of Preferred Stock are subject to redemption by the Corporation at any time after the date of issuance thereof.

4.03        The Corporation shall provide written notice of redemption to the holders of the Preferred Stock on not less than five days’ written notice specifying the date on which the Preferred Stock shall be redeemed (the “Redemption Date”).  The Corporation may redeem a portion or all of the issued and outstanding shares of Preferred Stock; provided, that in the event that fewer than all of the outstanding shares of Preferred Stock are redeemed, such redemption shall be pro rata determined on the basis of the number of shares of Preferred Stock held by each holder reflected on the stock records and the total number of shares of Preferred Stock outstanding.

4.04        The redemption consideration for each share of Preferred Stock shall be the original purchase price per share, plus any accumulated but unpaid dividends, plus the premium payable pursuant to subsection 4.05, if any.

4.05        The Corporation shall pay a premium upon redemption for Preferred Stock redeemed within three years of issuance, as follows:

(a)          Preferred Stock redeemed within one year of issuance shall receive a 30% premium on the original purchase price upon redemption;

(b)          Preferred Stock redeemed more than one year after issuance, but within two years shall receive a 20% premium on the original purchase price upon redemption; and

(c)          Preferred Stock redeemed more than two years after issuance, but within three years shall receive a 10% premium on the original purchase price upon redemption.

 

B-2

  

  

  

 

4.06        Redemption of the Preferred Stock shall be made in the following manner:

(a)          The Corporation shall notify the holders of the Preferred Stock of the Corporation’s intent to redeem the Preferred Stock.  Such notice shall include a statement of the number of shares of Preferred Stock to be redeemed and the manner in which the redemption consideration is to be paid.

 

(b)          On the Redemption Date, all shares of Preferred Stock subject to redemption shall be automatically redeemed.  The holder of any shares of Preferred Stock so redeemed shall be required to tender the certificates representing such shares, duly endorsed, to the Corporation or its agent in exchange for delivery of the redemption consideration.

5.           Additional Provisions

5.01        No change in the provisions of the Preferred Stock set forth in this Designation affecting any interests of the holders of any shares of Preferred Stock shall be binding or effective unless such change shall have been approved or consented to by the holders of a majority of the Preferred Stock in the manner provided in the corporation laws of the state of Nevada, as the same may be amended from time to time.

5.02        A share of Preferred Stock shall be transferable only on the books of the Corporation maintained at its principal office on delivery thereof, duly endorsed by the holder or by holder’s duly authorized attorney or representative or accompanied by proper evidence of succession, assignment, or authority to transfer.  In all cases of transfer by an attorney, the original letter of attorney, duly approved, or an official copy thereof duly certified, shall be deposited and remain with the Corporation.  In case of transfer by executors, administrators, guardians, or other legal representatives, duly authenticated evidence of their authority shall be produced and may be required to be deposited and remain with the Corporation in its discretion.  On any registration or transfer, the Corporation shall deliver a new certificate representing the share of Preferred Stock so transferred to the person entitled thereto.

5.03        Any notice required or permitted to be given to the holders of the Preferred Stock under this Designation shall be deemed to have been duly given if mailed by first class mail, postage prepaid, to such holders at their respective addresses appearing on the stock records maintained by or for the Corporation and shall be deemed to have been given as of the date deposited in the United States mail.

IN WITNESS WHEREOF, the foregoing Designation of Rights, Privileges, and Preferences of Series A Redeemable Preferred Stock of the Corporation has been executed as of this 7th day of September, 2010.

	  	  	
REVONERGY INC.

	
Attest:

	  	  
	  	  	  	  
	
By:

	  	
By:

	  
	  	
Kenneth G.C. Telford, Secretary

	  	
Ravi K. Daswani, President

	  	  	  	  

B-3

  

  

  

EXHIBIT C

LOCK-UP AGREEMENT

 

 

 

 

[Date]

 

 

Kodiak Capital Group, LLC

One Columbus Place, 25th Floor

New York, NY 10019

 

 

Ladies and Gentlemen:

 

 

This Lock-Up Agreement is being delivered to you in connection with the Preferred Stock Purchase Agreement dated as of August 25, 2010 (“Purchase Agreement”) and entered into by and among Revonergy Inc., a Nevada corporation (“Company”) and Kodiak Capital Group, LLC, a Delaware limited liability company (“Investor”), with respect to the purchase without registration under the Securities Act of 1933, as amended (the “Act”), in reliance on Section 4(2) of the Act and Rule 506 of Regulation D promulgated thereunder, of shares of the Company’s Series A Preferred Stock and related Securities.  Capitalized terms used herein without definition shall have the respective meanings ascribed to them in the Purchase Agreement.

 

In order to induce Investor to enter into the Purchase Agreement, the undersigned agrees that, for a period of ten Trading Days beginning on each date the Company delivers a Tranche Notice to Investor (the “Tranche Notice Date”) and ending on the Tranche Closing Date pursuant to the terms of the Purchase Agreement (the “Lock-up Period”), the undersigned will not, without the prior written consent of Investor, (a) sell, offer to sell, contract or agree to sell, hypothecate, pledge, purchase, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC promulgated thereunder (the “Exchange Act”) with respect to, any Common Stock of the Company or any securities convertible into or exercisable or exchangeable for Common Stock, or warrants or other rights to purchase Common Stock or any such securities, or any securities substantially similar to the Common Stock, (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or any such securities, or warrants or other rights to purchase Common Stock, whether any such transaction is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, or (c) publicly announce an intention to effect any transaction specified in clause (a) or (b).

 

The foregoing sentence shall not apply to (a) bona fide gifts, provided the recipient thereof agrees in writing to be bound by the terms of this Lock-Up Agreement, (b) dispositions to any trust for the direct or indirect benefit of the undersigned and/or the immediate family of the undersigned, provided that such trust agrees in writing to be bound by the terms of this Lock-Up Agreement, (c) sales made pursuant to any written sales plans established prior to the date of this Lock-Up Agreement in conformity with the requirements of Rule 10b5-1(c) promulgated under the Exchange Act or (d) exercise of options for Common Stock and the disposition (whether by sale, gift or otherwise) of Common Stock underlying such options.  Notwithstanding clause (a) above, the undersigned may make a bona fide gift of up to 10,000 shares of Common Stock to a charity or other non-profit entity and such charity or entity shall not be required to be bound by the terms of this Lock-Up Agreement; provided, however, that in the event the undersigned exercises options during the Lock-Up Period, the undersigned may not, during the Lock-Up Period, dispose of the number of shares of Common Stock underlying such exercised options equal to the number of shares of Common Stock gifted by the undersigned pursuant to this sentence during the Lock-Up Period.  For purposes of this paragraph, “immediate family” shall mean the undersigned and the spouse, any lineal descendent, father, mother, brother or sister of the undersigned.

 

The Company agrees to provide the undersigned with notice that the Company has delivered a Tranche Notice to Investor prior to, or simultaneous with, its delivery of the Tranche Notice to Investor.  Such notice shall provide the undersigned with the Tranche Notice Date and clearly indicate the beginning of the Lock-up Period.

 

C-1

  

  

  

 

Upon the termination of the Purchase Agreement, this Lock-Up Agreement shall be terminated and the undersigned shall be released from its obligations hereunder.

 

 

Sincerely,

 

 

 

 

Stockholder

Print Name:

Acknowledged and Agreed:

 

 

REVONERGY INC.

 

 

By:                                           

Name:                                           

Title:                                           

 

 

 

 

C-2

  

  

  

EXHIBIT D

OPINION

 

 

 Opinion to be reviewed by KLMR – Draft Opinion to be delivered separately]

D-1

  

  

  

EXHIBIT E

TRANCHE NOTICE 

 

 

Dated: [________], 20[__]

 

 

Re:  Tranche Notice

 

 

Ladies & Gentlemen:

 

 

Pursuant to the August 25, 2010 Preferred Stock Purchase Agreement (“Agreement”) between Revonergy Inc., a Nevada corporation (“Company”), and Kodiak Capital Group, LLC (“Investor”), Company hereby elects to exercise a Tranche.  Capitalized terms not otherwise defined herein shall have the meanings defined in the Agreement.

 

 

At the Tranche Closing, Company will sell to Investor [___________] Preferred Shares at $10.00 per share for a Tranche Amount of $[___________].

 

 

On behalf of Company, the undersigned hereby certifies to Investor as follows:

 

 

1.             The undersigned is a duly authorized officer of Company;

 

 

2.             The above Tranche Amount does not exceed the Maximum Tranche Amount; and

 

 

3.             All of the conditions precedent to the right of the Company to deliver a Tranche Notice set forth in Section 2.3(d) of the Agreement have been satisfied.

 

 

IN WITNESS WHEREOF, the Company has executed and delivered this Tranche Notice as of the date first written above.

 

 

REVONERGY INC.

By:                                                                

Name:                                                                

Title:                                                                

E-1Exhibit 10.16

 

CONFIDENTIAL TREATMENT REQUESTED

 

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED IS OMITTED

AND NOTED WITH “****”.

AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN
PROVIDED TO THE

SECURITIES AND EXCHANGE

COMMISSION.

 

DISTRIBUTION AGREEMENT

 

This distribution agreement (this “Agreement”) is
entered into as of October 31, 2001 by and between Bristol-Myers Squibb Pharma
Company, a general partnership organized under the laws of the State of
Delaware (“BMS”) and Medi-Physics Inc., doing business as Amersham Health, a
corporation organized under the laws of the State of Delaware (“NA”).

 

RECITALS:

 

BMS has developed
and is the manufacturer of certain terminally
sterilized Technetium (Tc-99m) generators, Gallium Citrate Ga-67 Injection, and
Xe-133 gas products and possesses certain unique and valuable technology,
know-how and other information relating to the manufacture and sales of such
products.

 

NA is, among other things, presently engaged in the
business of marketing and selling various radiopharmaceutical products and has
substantial experience with respect thereto.

 

BMS desires to grant, and NA desires to obtain,
under the terms and conditions of this Agreement, the right to purchase from
BMS and the non-exclusive right to market, distribute and sell such generators,
Gallium Citrate Ga-67 Injection, Xe-133 gas products and related accessory
products in the territory as hereinafter defined.

 

NOW, THEREFORE, in consideration of the convenants
and agreements hereinafter set forth, the parties hereto agree as follows:

 

ARTICLE 1. Appointment as
Distributor

 

BMS hereby grants, to NA, under the terms and
conditions of this Agreement, the non-exclusive right to market, distribute and
sell the terminally sterilized Technetium (Tc-99m) generators, Gallium Citrate
Ga-67 Injection and Xe-133 gas products and accessory products

 

1

 

hereafter identified on Exhibit A attached hereto (“Products”)
in the ****, to include the ****. In addition BMS agrees to supply to NA
Radiopharmacies in ****, solely for unit dose preparation in ****, those Tc-99m
Generators, Ga-67 and Xe-133 Products listed on Exhibit A. NA Radiopharmacies
in **** are defined as those entities in which NA has at least a ****% ownership
position. In addition, BMS
agrees to supply Products to those NA non-radiopharmacy accounts that are under
contract on the date of this Agreement and listed on Exhibit F, until the
expiration of such contract with the NA non-radiopharmacy account. Hereinafter,
the term “Territory” shall refer to both **** and **** so described above.

 

ARTICLE 2. Supply of
Products

 

2.1           (a)
BMS agrees to manufactures and sell to NA **** of NA’s requirements for
Products and NA agrees to purchase **** of its requirements for Products from
BMS.

 

(b) The parties are aware that BMS utilizes a ****
source for supply of Mo-99, and that BMS is required to purchase ****% of its requirements of Mo-99m from that
source. BMS agrees to use commercially reasonable efforts to find an
established backup sources for Mo-99 in the event BMS’s supplier fails to
provide BMS’s  requirements.

 

2.2           All
orders for purchases of Products by NA shall be submitted on NA’s standard
purchase order form as from time to time in use by NA (“Purchase Order”). A
copy of NA’s current form of Purchase Order is attached hereto as Exhibit B.
The terms of this Agreement shall take precedence over any standard terms of any Purchase Order where in conflict.

 

2.3           Upon
the Effective Date (as defined in Section 9.1 hereof) and no later than **** (****)
days prior to each **** during the term of this Agreement, each **** NA shall
provide BMS with a written forecast of the numbers and type of Products which
NA expects to purchase from BMS during the forthcoming calendar year, as the
case may be (the “Annual Forecast”).

 

2

 

2.4           NA
shall place firm Firm Orders, setting forth the quantities, delivery schedules
and dates, and its shipping instructions on the Wednesday prior to the
following Monday through Saturday shipping cycle. Once placed by NA, such Firm
Orders may be increased or decreased only with prior BMS approval. Subject to NA’s limited right to adjust Firm
Orders set forth in the previous sentence, such Firm Orders shall constitute
binding contractual obligations of NA.

 

2.5           Although
an Annual Forecast or Quarterly Forecast shall not constitute a binding
obligation upon NA to order the quantities specified therein, NA agrees to use
all reasonable efforts to make each Annual Forecast and Quarterly Forecast a
reasonably accurate prediction of the number and mix of Products NA will
actually order for delivery in the relevant period pursuant to its Firm Orders.

 

2.6           BMS
shall use commercially reasonable efforts to ship Products pursuant to NA’s
Firm Orders. Tc-99m generators shall be made available for shipment ****  BMS facility, Billerica, MA each day of
manufacture. Days of manufacture of Tc-99m generators are currently ****, ****,
****, **** and ****. Any BMS initiated, permanent changes in the manufacturing schedule
shall be mutually agreed upon, prior to implementation. Xe-133 gas products
shall be made available for shipment ****  BMS
facility, Billerica, MA each **** calibrated for the following ****. Gallium
Citrate Ga-67 Injection products shall be made available ****, calibrated for
the following ****. In the event BMS is unable to deliver all product
requirements on a given day, BMS will allocate product to Nycomed in proportion
to Nycomed’s share of total demand. In the event that delivery of a Product is
delayed more than **** hours past the agreed upon local delivery time, BMS will
reduce the price NA pays for such Product by ****%. However, after **** (****)
hours delay, NA shall not be required to accept such Product and may make arrangements
with BMS to return unopened Product for **** credit. The foregoing shall not apply to delays caused by Force Majeure events such as  weather conditions, effecting
transportation of components or Products, for which there will be no price
reduction. Following the **** hour period outlined above, in the

 

3

 

event that NA is required to find an alternate source of Product, BMS
shall pay the difference between BMS’s price under this Agreement and the price
NA is required to pay to obtain such Product, up to a limit of ****% of BMS’s
original price.

 

2.7           The
purchase prices to be charged NA for calendar year 2001 are shown in Exhibit Cl
and the mechanism to calculate future pricing for each Product is set forth in
Exhibit C2. Included in the prices of the Products are:

 

(a)   **** (****)
external generator shields per initial generator standing order (A25);

(b)   **** (****)
elution shields per initial generator standing order (A14);

(c)   **** (****)
packs of any combination of saline and evacs (A15, A17 or A3) per each received
generator standing order.

(d)   BMS
assures that the prices charged to NA for each Product shall recognize NA’s
proportion of total BMS volume for each product.

 

2.8           Delivery
of Products to NA hereunder shall be made by BMS via Federal Express, Priority
Overnight Service from BMS’s manufacturing facility located at 331 Treble Cove
Road, North Billerica, Massachusetts. If so requested by NA, BMS will arrange
for alternative shipment of Products in accordance with NA’s shipping
instructions contained in a Firm Order. NA shall reimburse BMS for the
difference between Federal Express and any payments made to such alternative
carriers by BMS on behalf of NA at the actual cost of such payments. BMS shall
incur no liability of any nature whatsoever with respect to its performance of
shipping duties on NA’s behalf other that because of BMS’s gross negligence.

 

2.9           All
payments for Products by NA shall be made within **** (****) days after receipt
of invoice.

 

ARTICLE 3. Distribution
and Sale of Products

 

3.1           NA
shall be responsible for compliance with all federal and state rules and regulations
which relate to the sale, promotion, distribution, use and final disposition of
Products

 

4

 

in the Territory. All communications that NA, its subdistributors,
dealers, agents, or affiliates make about the Products in promotional materials
or otherwise shall be consistent with the New Drug Applications or other
governmental registrations for the Product, fully truthful, based on documented
facts, and fairly balanced. NA, its subdistributors, dealers, agents, and
affiliates shall not under any circumstances state or imply in promotional
materials or otherwise that the Xenon gas vials purchased by NA hereunder can
be used with Xenon gas delivery systems other than those purchased by NA
hereunder. BMS agrees to supply **** **** (****) Xenon gun per new customer.

 

3.2           NA
shall ensure that BMS receives a copy of the license renewals or amendments of
each NA customer to which Products are to be shipped directly by BMS
authorizing their receipt and use of the Products in order to keep current
BMS’s present file of such licenses (other than in cases where the relevant
regulatory authorities permit shipment notwithstanding the failure to supply or
provide such copies). BMS shall not be obligated to ship to such NA customers
and shall, immediately upon receiving the order from NA, verify the NA
customer’s licensed status and notify NA immediately if such inability to ship
exists so NA may take such steps as are available to it to remedy the position.
Such refusal to ship to a customer, whose license file in BMS’s custody is not
current and which defect is not remedied by NA, shall not be deemed an
inability or failure on BMS’s part to deliver Product in a timely fashion in
order to meet NA’s required deadlines.

 

3.3           NA
agrees to provide to BMS copies of NA’s  initial promotional literature related
to Products for BMS to transmit to FDA. BMS will play no role in obtaining
approval of that material other than taking any administrative action necessary
because of BMS’s ownership of the registration.

 

3.4           NA
shall have the sole right to determine the resale price, discount and any other
terms and conditions for NA’s
resale of Products. NA shall have complete control over the manner and methods
of the marketing, distribution and sale of Products, and NA may distribute and
sell Products directly or through subdistributors, dealers, agents or its
affiliates and may hire

 

5

 

or retain marketing or other experts to advise and assist NA in the
distribution and sale of Products. Except as specifically stated herein, BMS shall play no role in NA’s
marketing, distribution and sale of Products.

 

3.5           Prior
to use of any label, labeling, advertising or promotional item related to the
Products (hereinafter referred to collectively as “Product Information”) by NA,
its subdistributors, dealers, agents, or affiliates, including but not limited
to any
package insert, product label, detail aid, direct mail piece,
file card, journal article, or reminder advertisement, NA shall submit a sample
of the Product Information to BMS for review. Provided, however that:

 

(a) NA shall not submit any information about
pricing of Products to BMS. If a sample of Product Information contains pricing
information, NA shall redact that information from the sample prior to
providing it to BMS; and

 

(b) BMS shall review the Product Information solely
for the following purposes: (1) to ensure compliance with the terms of BMS’s
New Drug Applications or other governmental registrations for the Products; (2)
to ensure that the Product Information is within the terms of the labeled
indications for the Products and is otherwise consistent with the approved
package inserts for the Products; and (3) to ensure that the Product
Information is not likely to give rise to any formal or informal action,
complaint or comment by or from the United States FDA or the Canadian HPB
regarding the Product Information or the Products; and

 

(c) Review by BMS of a sample of Product Information
shall not serve as admission, a representation.
or evidence thereof,
by BMS, that the Product Information: (1) is correct, accurate, or complete; or
(2) is within the scope of or consistent with the Product claims made by BMS;
or (3) is in compliance with the terms of this Agreement. Review of Product
Information by BMS shall not in any way alter or affect the indemnity given by
NA pursuant to Section 6.5 hereunder.

 

(d) NA shall provide BMS a sample of all Product
Information and BMS shall have fifteen (15) working days after receiving the
sample within which to review and comment on the Product Information. All
comments made by BMS shall be binding on NA, its

 

6

 

subdistributors, dealers, agents and affiliates; which shall implement
and incorporate into the Product Information all comments made by BMS. If BMS
does not respond within fifteen (15) working days, NA, its subdistributors,
dealers, agents, or affiliates may use the Product Information unchanged.

 

3.6           As
market considerations dictate, BMS and NA will consider the implementation of
depleted Uranium shielded Technetium-99 Generators.

 

ARTICLE
4. Trademarks

 

4.1           BMS
hereby grants to NA and NA hereby accepts the right to resell the Products supplied
by BMS to NA in packages bearing the trademarks listed in Exhibit D
(“Trademarks”) and in promotional materials related to such Products. The
rights granted NA hereunder to use the Trademarks shall in no way affect BMS’s
ownership of such Trademarks. No other right, title or interest in the
Trademarks is established hereby, and nothing herein shall be construed to
grant any right or license to NA to use the BMS logo or the BMS trade name,
other than as specifically set forth herein. The parties agree and understand
that this Section 4.1 does not expand the rights granted to NA under Article 1.

 

4.2           NA
shall not make any use or take any action with respect to the Trademarks to
prejudice or infringe BMS’s rights thereto including the use of any confusingly
similar trademark and shall forthwith, upon objection by BMS, desist from any
use thereof or action therewith which is in violation of this Agreement.

 

4.3           NA
will only market the Products using the relevant Trademarks during the term of
this Agreement. Upon termination or expiration of this Agreement, NA will cease
all use of the Trademarks and the license to use any such Trademarks granted
hereunder shall immediately cease and be deemed canceled.

 

7

 

4.4           NA
will use the Trademarks in strict accordance with the instructions given by BMS,
and shall not make any changes in connection therewith without first obtaining
BMS’s written consent. NA further agrees that at all times the Trademarks shall
be used in accordance with good trademark practice, including notation of the
fact that they are trademarks belonging to BMS and use of the appropriate
notice of registration. BMS reserves the right to unilaterally determine the
adequacy of the use and protection given the Trademarks by NA as set forth
herein.

 

4.5           NA
shall promptly notify BMS, in writing, of any conflicting use of, and applications or
registrations for, any of the Trademarks, or any acts of infringement, or acts
of unfair competition involving the Trademark, after such matters are brought
to its attention or it has knowledge thereof. NA further agrees to assist BMS,
at BMS’s expense, in registering or perfecting BMS’s rights to the Trademarks
in the Territory.

 

4.6           In
the event of any claim or litigation by a third party against NA alleging that
any of the Trademarks imitates or infringes a trademark of such third party or
is invalid, NA shall promptly give notice of such claims or litigation to BMS
and BMS shall assume responsibility for and control of the handling, defense,
or settlement thereof. NA shall cooperate fully with BMS during the pendency of
any such claim or litigation. BMS shall keep NA notified of the current status
of any trademark claim, litigation or infringement of any of the Trademarks and
shall permit NA to assume the handling, defense or settlement thereof if BMS
declines to do so.

 

ARTICLE 5. Quality
Control and Governmental Approvals

 

5.1           All
Products delivered to NA hereunder shall be manufactured in accordance with Current
Good Manufacturing Practices as required by the United States Federal Food,
Drug and Cosmetic Act and pursuant to applicable rules and regulations of the
United States Food and Drug Administration (“FDA”) when applicable. BMS shall
manufacture and supply the Products in accordance with the Quality Document
attached here as Exhibit E. Each product lot of

 

8

 

Products shall be inspected and tested by BMS prior to shipment to NA
or its customers. A certificate of Compliance will be forwarded to NA after
each manufactured lot is completed.

 

5.2           As
further set forth herein; NA shall have the right to replacement of or refund
for Products, up to the expiration date of such Products, if such Products fail
to meet BMS’s specifications as set forth in BMS’s NDA for such Products or are
not of merchantable quality. NA will promptly notify BMS by telephone and
telecopy of NA’s request for replacement or refund. Such notice shall specify
with particularity the nature of the nonconformance and NA will have the
Product returned promptly to.BMS for examination at BMS’s expense. Provided that NA promptly returns
the Products to BMS, BMS will promptly replace the Products in question if
requested by NA, determine any nonconformance of the returned Products and
report back to NA.

 

In the event that BMS disagrees with NA regarding
whether the Products are nonconforming and the parties are unable to resolve
the dispute, the Products or samples thereof will be submitted to a qualified
independent laboratory agreed upon by the parties. The laboratory will analyze
the Products or samples in a manner agreed upon by the parties and the results
of that analysis will be a binding determination of whether the Products were
or were not nonconforming. If it is determined that the Products were
nonconforming, BMS shall bear the cost of the analysis, as well as either
providing a refund or replacement Products to NA. If it is determined that the
Products were not nonconforming NA shall bear the cost of the analysis, shall
not be entitled to any refund on the Products and shall pay BMS for any
replacement Products provided by BMS.

 

5.3           All
materials and components used in the fabrication of Products shall be traceable
by lot number and purchase order invoice number.

 

ARTICLE 6. Warranties.
Indemnities and Insurance

 

6.1           BMS
warrants to NA that all Products purchased by NA under this Agreement:

 

9

 

(a) shall be free and clear of all liens, claims,
encumbrances, pledges, security interests or other adverse interests of third
parties,

 

(b) shall be manufactured, supplied and delivered by
BMS with all necessary skill and expertise using qualified personnel so as to
comply with all applicable regulatory requirements,

 

(c) shall be of good and merchantable quality, and
free from defects in material and workmanship;

 

(d) shall be manufactured in accordance with the
specifications set forth in BMS’s NDA, and

 

(e) shall be manufactured in accordance with the
Current Good Manufacturing Practices and other applicable FDA rules and
regulations.

 

6.2           (a)
BMS shall defend, indemnify and hold NA, its subdistributors, dealers, agents or
affiliates, harmless from any and all demands, claims, actions, suits,
judgments, decrees, proceedings, liabilities, costs, losses, damages and
expenses, including, without limitation, court costs and attorneys’ fees, at
any time resulting to any of them as a result of or in connection with (a) any
Products which were nonconforming, damaged, or defective at time of delivery to
NA whether claimed by or established in favor of any third parties, including
purchasers, and (b) any breach by BMS of the warranties provided for herein.

 

(b) NA shall promptly notify BMS upon receipt by NA
of any claim or demand which NA has determined has given or could give rise to
a right of indemnification under this Agreement. If such claim or demand
relates to a claim or demand asserted by a third party against NA, BMS shall
have the right to employ such counsel as is reasonably acceptable to NA to
defend any such claim or demand asserted against NA, and BMS shall have control
over the conduct of the defense of the claim or demand, provided, however, that
BMS shall not settle such claim or demand without the consent of NA unless such
settlement requires no more than a monetary payment for which NA is fully
indemnified under this Agreement or involves other matters not binding upon NA.
NA shall have the right to participate at its cost in the defense of any said
claim or demand. So long as BMS is defending in good faith any such claim or
demand,

 

10

 

NA shall not settle such claim or demand. NA shall fully cooperate with
BMS during the pendency of the claim or demand and shall make available to BMS
and its representatives all records and other materials reasonably required by
them for their use in contesting any claim or demand asserted by third party
against NA. Whether or not BMS  so elects to defend any such claim
or demand, NA shall not have any obligation to do so and NA shall not waive any
rights it may have against BMS hereunder with respect to any such claim or
demand by electing or failing to elect to defend any such claim or demand. NA’s
subdistributors, dealers, agents or affiliates shall also be bound by this
section.

 

6.3           The
obligation of BMS to indemnify and defend shall not extend to claims or demands
to the extent they are attributable to the independent negligence or
intentional malfeasance of NA, its subdistributors, dealers, agents, or
affiliates, nor to any claims or demands to the extent that they are attributable
to or arising out of statements or actions made by NA, its subdistributors,
dealers, agents or affiliates with respect to the Products. The obligation to
BMS to indemnify and defend shall also not apply to any claims or demands to
the extent that they are attributable to any breach by NA of the terms of this
Agreement.

 

6.4           BMS
represents that it is self-insured for the activities to be carried out under
this Agreement and that it maintains sufficient reserves covering these
activities.

 

6.5           (a)
NA shall defend, indemnify and hold BMS, its directors, officers, agents, affiliates,
and employees, harmless from any and all demands, claims, actions, suits,
judgments, decrees, proceedings, liabilities, costs, losses, damages and
expenses, including, without limitation, court costs and attorneys’ fees, at
any time resulting to any of them, as a result of or in connection with (a) any
negligence or intentional malfeasance by NA, its subdistributors, dealers,
agents, or affiliates, and (b) any representation made or other action taken by
NA, its subdistributors, dealers, agents, or affiliates related to marketing,
selling, or distributing the Products, which are outside the scope of or
inconsistent with any Product claims made by BMS, and (c) any breach by NA of
the terms of this Agreement. This obligation of NA to indemnify

 

11

 

 

and defend shall not apply to the extent that claims are attributable
to the independent negligence or intentional malfeasance of BMS.

 

(b) BMS shall promptly notify NA upon receipt by BMS
of any claim or demand which BMS has determined has given or could give rise to
a right of indemnification under this Agreement. If such claim or demand
relates to a claim or demand asserted by a third party against BMS, NA shall
have the right to employ such counsel as is reasonably acceptable to BMS to
defend any such claim or demand asserted against BMS and NA shall have control
over the conduct of the defense of the claim or demand; provided, however, that
NA shall not settle such claim or demand without the consent of BMS unless such
settlement required no more than a monetary payment for which BMS is fully indemnified
under this Agreement or involves other matters not binding upon BMS. BMS shall
have the right to participate at its costs in the defense of any such claim or
demand. So long as NA is defending in good faith any such claim or demand, BMS
shall not settle such claim or demand. BMS  shall fully cooperate with NA
during the pendency of the claim or demand and shall make available to NA and
its representatives all records and other materials reasonably required by them
for their use in contesting any claim or demand asserted by third party against
BMS. Whether or not NA so elects to defend any such claim or demand, BMS shall
not have any obligation to do so and BMS shall not waive any rights it may have
against NA hereunder with respect to any such claim or demand by electing or
failing to elect to defend any such claim or demand. BMS’s subdistributors,
dealers, agents, or affiliates shall also be bound by this section.

 

(c) NA represents that it is self-insured for the
activities to be carried out under this Agreement and that it maintains
sufficient reserves covering these activities.

 

6.6           NA
will notify BMS of any adverse drug experience associated with the Products of
which NA, its subdistributors, dealers, agents, or affiliates become aware.
Such notifications will be made in writing, in a manner reasonably agreed by
the parties, by means which afford the sender evidence of receipt by BMS within
three (3) working days of initial receipt of the report by NA, its
subdistributor, dealer, agent, or employee. Such means of notification may
include Express Mail, Electronic Mail, courier, or facsimile, but are not
so-limited. Advance notification of any fatal or immediately life-threatening
experience will be given by telephone. NA is

 

12

 

responsible for insuring prompt follow-up, as necessary to provide BMS
with reasonably complete information on each such adverse drug experience, by
the same means and within the same time frame of receipt.

 

Any communication to BMS under the terms of this
Section 6.6 shall be directed to the attention of the following individual or
to his designee or successor:

 

Regulatory Affairs

Bristol-Myers Squibb Pharma Company

331 Treble Cove Road

North Billerica, Massachusetts 01862

Telephone: 978-671-8361

Telecopy: 978-663-6897

 

“Adverse drug experience” shall mean any unfavorable
and/or unintended change in the structure (signs), function (symptoms), or
chemistry (laboratory data) of the body temporally associated with the use of
Product or of a derivative thereof in humans, whether or not considered drug
related, including the following: an adverse experience occurring in the course
of the use of a drug in professional practice, an adverse experience occurring
from drug overdose, whether accidental or intentional, an adverse experience
occurring from drug withdrawal, and any significant failure of expected
pharmacological action. (Failure of a radiopharmaceutical product to localize
as expected is not regarded by BMS as an adverse experience, but rather as a
complaint, which is referred to BMS’s Marketing and Technical Services
personnel for further investigation.)

 

ARTICLE 7. Representation
and Warranties.

 

7.1           BMS
hereby represents and warrants to NA as follows:

 

(a) BMS has the full power, authority and legal
right to enter into this Agreement; this Agreement has been duly authorized,
executed and delivered by BMS; and this Agreement constitutes a legal, valid
and binding obligation of BMS, enforceable against BMS in
accordance with its terms.

 

13

 

(b) BMS has executed no agreement in conflict
herewith.

 

(c) The distribution and sale of the Products by NA
will not infringe the patents or intellectual property rights of any third
party.

 

7.2           NA
hereby represents and warrants to BMS that NA has the full power, authority and
legal right to enter into this Agreement; this Agreement has been duly
authorized, executed and delivered by NA; this Agreement constitutes a legal,
valid and binding obligation or NA enforceable against NA in accordance with
its terms; and NA has executed no agreement in conflict with the terms of this
Agreement.

 

ARTICLE 8. Confidentiality

 

Any and all proprietary information with respect to
the Products or the business affairs and activities of either party hereto
(“Proprietary Information”) which is furnished or disclosed in connection with
the Agreement by such party (“Disclosing Party”) to the other party hereto
(“Receiving Party”), including, without limitation, the specifications for the
Products, shall remain the property of the Disclosing Party and shall be
treated as confidential. Receiving Party shall not use such Proprietary
Information for its own benefit except as specified in this Agreement and shall
not disclose such Proprietary Information to others, except to those of its
employees whose duties so require, in such event taking all precautions which
are reasonably necessary to prevent the unauthorized disclosure of such
Proprietary Information by such persons. Information shall not be deemed to be
Proprietary Information and such restrictions shall not apply to any such
information (i) which is, or subsequently may become, within the knowledge of the general public,
without the fault of the Receiving Party; (ii) which may be known to the
Receiving party at the time of receipt thereof from the Disclosing Party as
shown by competent written records, (iii) which may be proved to have been
developed by the Receiving Party, independently and wholly without resort to
the Proprietary Information of the Disclosing Party, as shown by competent
written records; or (iv) which may subsequently be rightfully obtained from
sources other than the Disclosing Party and without confidential restriction in
favor of such transmitting party. The parties’ respective obligations under
this Article 8 shall continue after the expiration or termination of this
Agreement for any reason.

 

14

 

ARTICLE 9. Term and
Termination

 

9.1           Unless
earlier terminated as provided in this Agreement, the initial term of this Agreement
shall commence as of the Effective Date and conclude on December 31, 2005.
Thereafter, this Agreement will automatically renew for three (3) year periods.
Notwithstanding the foregoing, this Agreement
may  be  terminated at any time by BMS on three (3) years written
notice to NA or by NA on six (6) months written notice to BMS.

 

9.2           Upon
the happening of any of the following .events, either party shall have the right to
terminate this Agreement upon written notice of such termination to the other
party:

 

(a) Any material breach by the other party of this
Agreement, which material breach continues for a period of thirty (30) days
after the non-defaulting party shall have given notice thereof to the
defaulting party, or

 

(b) The other party becomes insolvent, is
adjudicated as bankrupt or otherwise seeks or receives protection under the
bankruptcy laws of the United States, has a receiver or trustee appointed for
all or part of its assets and business, executes and delivers an assignment for
the benefit of its creditors or is liquidated, dissolved or wound-up or

 

(c) The continuance of an event of force majeure
for a period of more than sixty (60) days.

 

9.3           The
objective of this Agreement is to realize in an economical and reasonable way
the interests and requirements of both parties. If at any time during the term
of this Ageement, this objective is no longer met due to: ·

 

(a) regulatory changes(s), or economic
circumstances, which could not have been foreseen at the time of execution of
this Agreement causing undue and prolonged hardship; or

 

(b) any substantial increase in Seller’s direct or
indirect cost relating to Uranium targets or radioactive waste disposal;

 

15

 

(c) changes in the selling price effected by the
entrance into the market of sellers capable of meeting the volume commitments
contemplated under this Agreement; then the parties shall negotiate in good
faith in an effort to modify this Agreement in accordance with any of the
matters described above and such negotiations shall commence within **** (****)
days of one party’s written notice to the other of (a) and/or (b) above. During
any negotiation period, the pricing increments defined in Exhibit C will
continue in effect.

 

In the event the parties are unable to agree upon a
satisfactory modification of this Agreement within **** (****) days of
commencement of negotiations (“negotiation period”), the party requesting the
modification may terminate this Agreement within **** (****) days following
expiry of the negotiation period by providing **** (****) days written notice to
the other party.

 

9.4           The
warranties and indemnities contained in this Agreement shall survive any expiration
or termination hereof, as shall the confidentiality obligations of the parties
pursuant to Article 8 hereof. Otherwise, upon expiration or termination of this
Agreement as provided in this Article 9, except as expressly provided herein,
the parties shall have no further liabilities, duties or obligations under this
Agreement, except for any liabilities, duties or obligations which may have
arisen prior to such expiration or termination.

 

ARTICLE 10. Force Majeure

 

10.1         Neither
party will be liable for any failure to fulfill any term or condition of this
Agreement, nor will such failure constitute a breach of or default under this
Agreement, if fulfillment has been delayed, hindered or prevented by an event
of force majeure, including, without limitation, any war, riot, strike,
lock-out or other industrial dispute, acts of the elements, acts of any
government or agency hereof (including the enactment of any new laws, rules or
regulations), sabotage or industrial accident, plant breakdown or failure of
equipment, inability to obtain equipment, fuel, power, materials or
transportation, or by any similar circumstances beyond its reasonable control.

 

16

 

10.2         Promptly
following the date that any event of force majeure commences, the party
concerned will advise the other party in writing of the date and nature of the
event and the period of time such event is expected to continue. During the
existence of such event, the duties and obligations of the parties under this
Agreement shall be suspended and the parties will take all reasonable action to
assure resumption of normal performance under this Agreement as soon as
possible.

 

ARTICLE 11. Assignment

 

This Agreement and all rights and obligations
arising hereunder may not be assigned or otherwise transferred by either party
whether by operation of law or otherwise, unless the other party has given its
written consent thereto, which consent shall not be unreasonably withheld, and
any such purported assignment or transfer without the other party’s written
consent shall be null and void. Notwithstanding the foregoing, a party hereto
may assign this Agreement and all rights and obligations arising hereunder in
connection with the sale of all or substantially all of its business.

 

ARTICLE 12. General
Provisions

 

12.1         The
relationship of BMS and NA under this Agreement shall be that of independent
seller and purchaser, and nothing contained in this Agreement and no action taken
by either party to this Agreement shall be deemed to constitute either party or
any of such party’s employees, agents or representatives to be an employee,
agents or representative of the other party or shall be deemed to create any
partnership, joint venture, association or syndicate between the parties, or
shall be deemed to confer on either party any express or implied right, power
or authority to enter into any agreement of commitment, express or implied, or
to incur any obligation or liability on behalf of the other party.

 

12.2         Except
as specified in Section 6.6 above, any notice, claim; demand, request or other
communication required or permitted under this Agreement shall be valid and
effective

 

17

 

only if given by written instrument which is personally delivered, sent
by facsimile, courier or registered or certified mail, postage prepaid to the
addressee as follows:

 

If to BMS, to:

 

Bristol-Myers Squibb Pharma Company 

Radiopharmaceutical Division

331 Treble Cove Road

North Billerica, Massachusetts 01862 

Attention: Vice President, Manufacturing

Telecopy: 978-671-9577

 

If to NA, to:

 

Medi-Physics, Inc.

2636 South Clearbrook Drive 

Arlington Heights, Illinois 60005

Attention: President

Telecopy: 708-593-8010

 

Except as specified in Section 6.6 above, any notice,
claim, demand, request or other communication given as provided in this Section
12.2, if given personally, shall be effective upon delivery; if given by facsimile,
shall be effective one (1) day after transmission; and if given by courier,
shall be effective two (2) days after deposit with the courier; and if given by
mail, shall be effective five (5) days after deposit in the mail. Either party
may change the address at which it is to be given notice by giving written
notice to the other party as provided in this Section 12.2.

 

12.3       This
Agreement, together with the Exhibits attached hereto, constitutes the entire
agreement, and supersedes all prior agreements and understanding, both written
and oral, between the parties with respect to the subject matter of this
Agreement; and this Agreement may not be modified or amended except by an
instrument in writing executed by the parties hereto.

 

18

 

12.4         No
waiver, forbearance or failure by either party of its right to enforce any
provision of this Agreement shall constitute a waiver or estoppel of such
party’s right to enforce such provision in the future.

 

12.5         Unless
expressly provided otherwise herein, the remedies set forth in this Agreement
shall not be exclusive but shall be cumulative, and in addition to all other
rights and remedies provided by law.

 

12.6         This
Agreement shall be governed by and construed in accordance with the internal
laws of the State of Delaware, excluding the conflict of law provisions
thereof.

 

12.7         If
any provision of this Agreement shall be found invalid or unenforceable, in
whole or in part, by a court of competent jurisdiction, then such provision
shall be deemed to be modified or restricted to the extent and in the manner
necessary to render the same valid and enforceable, or shall be deemed excised
from this Agreement, as the case may require, and this Agreement shall be
construed and enforced to the maximum extent permitted by law, as if such
provision had been originally incorporated herein as so modified or restricted,
or as if such provision had not been originally incorporated herein, as the
case may be, provided that the basic intent of the parties has not thus been
rendered incapable of achievement.

 

IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the day and year first above
written.

 

	
   

  	
  MEDI-PHYSICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ [ILLEGIBLE]

  	
   

  
	
   

  	
   

  
	
   

  	
  Title: 

  	
  Vice President

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  BRISTOL-MYERS SQUIBB PHARMA COMPANY

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Donald J. Hayden

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Title: 

  	
  Executive Vice President,
  Health Care Group 

  	
   

  

 

19

 

 

EXHIBIT A

 

PRODUCTS

 

Tc-99M GENERATOR

 

	
  ITEM
  #

  	
   

  	
  DESCRIPTION

  
	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT. CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
  ****

  	
   

  	
  ****mCi UNIT, CALIBRATED @****

  
	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  SET OF **** ML SALINE ELUANT VIALS

  
	
  ****

  	
   

  	
  SET OF **** ML SALINE ELUANT VIALS

  
	
  ****

  	
   

  	
  SET OF **** ML EVACUATED COLLECTION VIALS

  
	
  ****

  	
   

  	
  LEAD ELUTION SHIELD

  
	
  ****

  	
   

  	
  MOLY CODDLE RADIATION REDUCER

  
	
  ****

  	
   

  	
  ALUMINUM
  ION INDICATOR KIT

  
	
   

  	
   

  	
   

  
	
  XENON-133

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  XE-133
  **** mCi , **** VIAL TUBE

  
	
  ****

  	
   

  	
  XE-133
  **** mCi , ****
  VIAL
  TUBE

  
	
  ****

  	
   

  	
  XE-133
  **** mCi , **** VIAL TUBE

  
	
  ****

  	
   

  	
  XE-133 **** mCi , ****
  VIAL TUBE

  

 

20

 

EXHIBIT A (cont’d)

 

PRODUCTS

 

XENON-133

 

	
  ITEM #

  	
   

  	
  DESCRIPTION

  
	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  XE-133 ****  mCi , **** VIAL TUBE

  
	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  XE-133 **** mCi , **** VIAL TUBE

  
	
  ****

  	
   

  	
  XE-133 **** mCi , **** VIAL TUBE

  
	
  ****

  	
   

  	
  XE-133 **** mCi , **** VIAL TUBE

  
	
  ****

  	
   

  	
  XE-133 **** mCi , **** VIAL TUBE

  
	
  ****

  	
   

  	
  XE-133 **** mCi , **** VIAL TUBE

  
	
   

  	
   

  	
   

  
	
  XGUN

  	
   

  	
  XENON GUN

  
	
   

  	
   

  	
   

  
	
  GALLIUM-67

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  **** mCi VIAL, CALIBRATED@ 1200
  EST. Day Of Calibration

  
	
  ****

  	
   

  	
  **** mCi VIAL, CALIBRATED@
  1200 EST. Day Of Calibration

  
	
  ****

  	
   

  	
  **** mCi VIAL, CALIBRATED@
  1200 EST. Day Of Calibration

  
	
  ****

  	
   

  	
  ****mCi VIAL, CALIBRATED@ 1200
  EST. Day Of Calibration

  
	
  ****

  	
   

  	
  ****mCi VIAL, CALIBRATED@ 1200
  EST. Day Of Calibration

  
	
   

  	
   

  	
   

  
	
  MHDLG

  	
   

  	
  HANDLING CHARGE PER ORDER

  

 

NOTES

 

·                                          DUPONT RESERVES
THE RIGHT TO ADD OR DELETE SPECIFIC ITEMS FROM ITS TOTAL PRODUCT PORTFOLIO
GIVING **** DAY NOTICE

 

·                                          ****=****, ****=****, ****=****, ****=****, ****=****

 

·                                          GENERATORS ARE
CALIBRATED ON ****

 

·                                          GA-67 IS
CALIBRATED FOR **** FOLLOWING **** RELEASE

 

·                                          XENON IS
CALIBRATED FOR **** FOLLOWING **** RELEASE

 

·                                          MOLY CODDLES
ARE ONLY SHIPPED VIA COMMON CARRIER (ROADWAY, ETC)

 

21

 

EXHIBIT B 

 

PURCHASE ORDER FORM

 

Lead Generator and Accessories Order Form

 

	
  Customer #

  	
   

  	
   

  
	
   

  	
   

  
	
  Customer PQ #

  	
   

  	
   

  
	
   

  	
   

  
	
  Customer Name

  	
   

  	
   

  
	
   

  	
   

  
	
  Address

  	
   

  	
   

  
	
   

  	
   

  
	
  City/State

  	
   

  	
   

  
	
   

  	
   

  
	
  Zip Code

  	
   

  	
   

  
				

 

	
  New
  Order:

  	
   

  
	
   

  	
   

  
	
   

  	
  Product

  	
   

  	
   

  	
  Qty

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  1st shipping date

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Sales order #

  	
   

  	
   

  
							

 

	
  Cancellation

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Product

  	
   

  	
   

  	
  Qty

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Last shipping date

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Sales order #

  	
   

  	
   

  
							

 

	
  Change

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Product

  	
   

  	
   

  	
  New Qty

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Product

  	
   

  	
   

  	
  New Qty

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Product

  	
   

  	
   

  	
  New Qty

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  New Size

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  1st shipping date

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Sales order #

  	
   

  	
   

  
								

 

	
  Comments

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  

 

22

 

EXHIBIT Cl

 

PRICING
**** THROUGH ****

 

	
  Item #

  	
   

  	
  PRICE

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Tc-99m GENERATOR

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  TC-99m ACCESSORIES

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  XENON-133

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  

 

23

 

EXHIBIT Cl (cont’d)

 

PRICING **** THROUGH ****

 

	
  Item #

  	
   

  	
  PRICE

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  XENON-133

  	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  XGUN

  	
   

  	
  $

  	
  ****

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  GALLIUM-67

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
  ****

  	
   

  	
  $

  	
  ****

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  MISCELLANEOUS

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  MHDLG

  	
   

  	
  $

  	
  ****

  	
   

  

 

24

 

EXHIBIT C2

 

A.                PRICES ARE PER ITEM AS
DESCRIBED IN EXHIBIT A

 

B.                  ADDITIONAL FREIGHT CHARGES.
WHERE REQUESTED AND APPROVED, WILL BE ADDED TO THE $**** MHLDG ITEM

 

C.                  WHEN NECESSARY TO SUBSTITUTE
FOR REQUESTED ITEMS DUE TO INVENTORY SHORTFALL, BMS WILL ADJUST PRICES FOR SUBSTITUTED
ITEMS TO REFLECT REQUESTED ITEMS TOTAL COST

 

D.                 **** PRICE
ADJUSTMENTS FOR EACH PRODUCT, EXPRESSED AS
A PERCENTAGE.  FOR **** COMMENCING ****,
AND IMPLEMENTED ON EACH SUBSEQUENT ****
WILL BE CALCULATED AS FOLLOWS:

 

1.                        COST, OF
MATERIALS PLUS ****% OF ****

2.                        NEW PRICING
INCORPORATING THE ABOVE WILL BE COMMUNICATED TO NA ON OCTOBER 1 TO ASSIST NA COST FORECASTING, THE OCTOBER 1
COMMUNICATION WILL INCLUDE ANTICIPATED BMS TIMING/INCREASE % ON APPLICABLE
PRODUCTS FOR THE COMING ****. THIS
INFORMATION MUST BE HELD IN THE STRICTEST CONFIDENCE BY NA

FOR EXAMPLE, IN THE EVENT THAT THE **** WAS EQUAL TO ****% AND DUPONT COMMUNICATED TO NA ON OCTOBER 1 THAT THE COST OF
MATERIAL FOR MO-99 INCREASED BY ****%,
THEN THE **** PRICE ADJUSTMENT
FOR MO-99, IMPLEMENTED ON ****,
WOULD BE CALCULATED AS FOLLOWS: ****
PRICE ADJUSTMENT = ****% + **** X ****% = ****%. AS
AN ADDITIONAL EXAMPLE IN THE EVENT THE ****
ON **** WAS ****% AND THE COST OF MATERIAL FOR
GA-67 INCREASED BY ****%. THEN
THE **** PRICE ADJUSTMENT FOR
GA-67, IMPLEMENTED ON ****,
WOULD BE ****%.

 

E.                   SEPARATE FROM THE **** PRICE ADJUSTMENT DESCRIBED ABOVE BMS
WILL PASS THROUGH ADDITIONAL PRICE ADJUSTMENTS WHEN BMS HAS ADJUSTED
ARMS-LENGTH UNBUNDLED PRICING TO NON-NA, SEGMENTS FROM THE LEVEL DEVELOPED IN THE
**** INCREASE PRICE ADJUSTMENT, AS
FOLLOWS:

 

1.                    BMS WILL PROVIDE **** MONTHS DOCUMENTED ASP CHANGE REALIZED
ASP CHANGE

2.                    **** DAYS FROM
PRESENTATION OF REALIZED ASP CHANGE, NA PRICING WILL BE ADJUSTED

3.                    SUCH ADJUSTMENT WILL BE THE
DIFFERENCE BETWEEN THE REALIZED ASP CHANGE AND THE **** PRICE ADJUSTMENT. WHETHER IT BE POSITIVE OR NEGATIVE.

4.                    FOR EXAMPLE, IN THE EVENT
THE REALIZED ASP CHANGE FOR MO-99 ON ****
WAS ****% AND THE **** PRICE ADJUSTMENT WAS EQUAL TO ****%. THEN THE ADDITIONAL PRICE
ADJUSTMENT FOR MO-99 WOULD BE IMPLEMENTED ON OCTOBER 1 AND WOULD BE CALCULATED AS FOLLOWS: ADDITIONAL
PRICE ADJUSTMENT = ****% - ****% = ****%.

5.                    ASP Calculation will be
carried out as follows:

 

25

 

For the purposes of calculating price changes, average
selling price (ASP) will be defined separately for each item and separately for
the **** and ****. In each case, the ASP for the
period in question will be defined as the total realized revenue, less
discounts and rebates, divided by the number of units sold. Free product
provided to customers in the form of a discount or incentive will count toward
the unit number but replacement product, to address product performance or
delivery issues, will not. Free or discounted product made available as part of
clinical trial support will also not count in the unit number.

 

6.                                       Example

 

BMS provides NA new pricing on October 1 to be effective the
following **** that is based
upon a ****% increase in the
cost of materials for MO-99, ****%
for Gallium-67, and ****% for
Xenon-133. The **** is ****%. BMS also provides NA on October 1 anticipated BMS timing
/increase % on MO-99, GA-67 and XE-133 for the coming calendar year as set forth below. The Price Increase
as a percentage of last year’s price is as follows:

 

A. **** Communication to NA October 1

 

	
   

  	
   

  	
  MO-99

  	
   

  	
  GA-67

  	
   

  	
  XE-133

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cost of Materials increase

  	
   

  	
  ****

  	
  %

  	
  ****

  	
  %

  	
  ****

  	
  %

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ****% August 1 ****

  	
   

  	
  ****

  	
  %

  	
  ****

  	
  %

  	
  ****

  	
  %

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  **** Increase

  	
   

  	
  ****

  	
  %

  	
  ****

  	
  %

  	
  ****

  	
  %

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  “Non-NA” Forecast Increase

  	
   

  	
  ****

  	
  %

  	
  ****

  	
  %

  	
  ****

  	
  %

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Timing

  	
   

  	
  ****

  	
   

  	
  ****

  	
   

  	
  ****

  	
   

  

 

Assume that the ****month weighted average ASP for MO-99 during the period from **** price increase is a Realized ASP
Change of ****%, and that the ****month weighted average ASP for
GA-67 and XE-133 from the ****
price increase is a Realized ASP Change of ****% and ****%
respectively. The off cycle price adjustment as a percentage of the calendar’s
year price is as follows:

 

26

 

B. “Off cycle” Communication to NA

 

	
  Communication Timing

  	
   

  	
  ****

  	
   

  	
  ****

  	
   

  	
  ****

  	
   

  
	
  Realized “Non NA” ASP
  Increase

  	
   

  	
  ****

  	
  %

  	
  ****

  	
  %

  	
  ****

  	
  %

  
	
  Adj. to NA Pricing

  	
   

  	
  ****

  	
  %

  	
  ****

  	
  %

  	
  ****

  	
  %

  
	
  Timing

  	
   

  	
  ****

  	
   

  	
  ****

  	
   

  	
  ****

  	
   

  

 

27

 

EXHIBIT D

 

TRADEMARKS

 

	
Trademark
  	
 
  	
Country
  	
 
  	
Registration Number
  	
 
  
	
 
  	
 
  	
 
  	
 
  	
 
  	
 
  
	
TECHNELITE
  	
 
  	
USA
  	
 
  	
1,812,837
  	
 
  
	
 
  	
 
  	
 
  	
 
  	
 
  	
 
  
	
TECHNELITE
  	
 
  	
Canada
  	
 
  	
424737
  	
 
  

 

28

 

EXHIBIT E

 

QUALITY DOCUMENT

 

1.                                      GUIDING PRINCIPLES

 

Regarding the working relationship between the Quality Departments of NA and BMS Pharmaceuticals (Medical Imaging) for the Product(s) (refer to the Appendix):

 

1.1                                 Unless otherwise specified, NA refers to NA Quality and the Contractor refers to BMS Pharmaceuticals (Medical Imaging) Quality.

 

1.2                                 The Contractor has the responsibility to evaluate/monitor any new U.S. NDA requirements and notify NA of any changes in requirements in a timely manner.

 

1.3                                 The Contractor has responsibility to operate within the Product registration documentation and shall provide Product that meets all criteria throughout its shelf life.

 

1.4                                 The Appendix of this document specifies the Product(s) currently covered by this Agreement. This Agreement may be amended as new products are added or deleted.

 

2.                                      MAINTENANCE OF COMPLIANCE BETWEEN THE PRODUCT REGISTRATION AND THE PROCESS

 

2.1                               Technical Changes

 

2.1.1                        The Contractor is responsible for maintaining a change control system that will:

 

2.1.1.1               review and approve all changes;

 

2.1.1.2               evaluate the impact of changes on validation status;

 

29

 

2.1.1.3               evaluate the impact of changes on product registration, and

 

2.1.1.4               evaluate the impact of changes on product safety and efficacy.

 

2.1.2                        The Contractor is responsible for maintaining a system to implement compendial changes.

 

2.2                               Other Changes

 

2.2.1                        All parties, prior to implementation, must approve proposed changes in the storage and/or shipping of the Product.

 

3.                                      BATCH RELEASE

 

3.1                                 The Contractor will manufacture and test the Product according to established, approved procedures and current Good Manufacturing Practices.

 

3.2                                 Batch review and release of the Product and all of its components will be the sole responsibility of the Contractor.

 

3.3                                 The Contractor will have a formal retest policy and procedure in place that is in accordance with applicable regulations.

 

3.4                                 The Contractor will notify NA, within 48 hours, in the event that any test reveals contamination, lack of sterility, or degradation beyond specifications in any batch of Product. The Contractor will file any reports required by the applicable regulations.

 

30

 

4.                                      BATCH DOCUMENTATION

 

4.1                                 Originals of all batch documents will be retained by the Contractor according to regulatory and Contractor requirements; these records will be maintained for a period of one (1) year following the Product lot’s expiration date.

 

5.                                      RETAIN SAMPLES

 

5.1                                 The Contractor shall retain, under proper storage conditions, samples of the Product as required by the regulations for a period of:

 

5.1.1                        At least three (3) months following the Product lot’s expiration date for radioactive products,

 

5.1.2                        At least one (1) year following the Product lot’s expiration date for non-radioactive products.

 

6.                                      STABILITY

 

6.1                                 The Contractor will ensure that a product monitoring (stability testing) program is in place for the Product.

 

6.1.1                        The Contractor is responsible for performing stability testing in accordance with the filed stability schedule. Samples shall be stored and tested at appropriate intervals, as described in the approved stability protocol.

 

6.1.2                        If a confirmed result indicates the Product has failed to remain within specifications, the Contractor is required to notify NA within three business days. Notification will include a discussion of the issues, available data, and a path forward.

 

31

 

6.1.3                        In all cases, the Contractor must investigate any confirmed out of specification (OOS) result. A copy of the completed investigation report shall be sent to NA within thirty business days of the initial confirmation of the OOS.

 

7.                                      COMPLAINTS

 

7.1                                 NA will receive and summarize all customer complaints in accordance with the regulations. Product complaints will be forwarded to the Contractor for evaluation and investigation. The Contractor will provide NA all appropriate and reasonable technical assistance necessary to respond to a complaint. Following investigation, the Contractor will summarize the investigation and provide within 60 days a report to NA. NA will provide a response to the complainant and provide a summary back to the Contractor. Within three working days of receipt, NA will promptly communicate to the Contractor, product complaint reports that may require reporting to the regulatory authorities. The Contractor has sole responsibility for determining when a regulatory authority must be notified of the results of a Product complaint.

 

8.                                      RECALL

 

8.1                                 The Contractor will maintain a procedure for handling product recalls.

 

8.2                                 NA has the responsibility to provide any data or information that could result in Product recall within an appropriate time frame. The Contractor will evaluate all information and has sole responsibility for the decision to recall any Product lot.

 

8.3                                 NA will provide to the Contractor any information required to perform a Product recall.

 

32

 

9.                                      ANNUAL PRODUCT REVIEW

 

9.1                                 Each year the Contractor will conduct an Annual Product Review, which will minimally contain for each Product manufactured:

 

9.1.1                        Total number of batches made, number of batches released, number of batches rejected, and number of batches recalled.

 

9.1.2                        A review and summary of customer complaints.

 

9.1.3                        A listing and discussion of any recalls.

 

9.1.4                        A listing and discussion of any changes.

 

9.1.5                        A listing and discussion of stability data.

 

9.1.6                        Overall discussion, evaluation and conclusions.

 

10.                               AUDITS

 

10.1                           NA may schedule periodic audits of the Contractor’s facilities. If requested, access for additional Product specific audits will be granted.

 

10.2                           NA shall have the right to visit the Contractor’s plant where the Product is manufactured on any business day upon reasonable prior notice to Contractor. During any such visit, NA shall have the right to audit the Contractor’s manufacturing and quality control procedures, records, reports, and facilities as well as any regulatory correspondence applicable to the Product to ensure that the Contractor complies with the Product registration and with Good Manufacturing Practices.

 

11.                               INSPECTIONS/LEGAL ACTIONS

 

11.1                           The Contractor shall notify NA of regulatory agency inspection results and/or legal actions

 

33

 

that impact the Product.

 

12.                               SUPPLIER QUALIFICATIONS

 

12.1                           The Contractor will maintain a formal supplier qualification and management program.

 

13.                               TRAINING

 

13.1                           Each person engaged in the manufacturing, processing, packing, or holding of the drug product shall have education, training, and experience, or any combination thereof, to enable that person to perform the assigned functions. Training shall be in the particular operations that the employee performs and in current applicable manufacturing regulations as they relate to the employee’s functions. Training in applicable manufacturing regulations shall be conducted by qualified individuals on a continuing basis and with sufficient frequency to assure that employees remain familiar with requirements applicable to them.

 

14.                               VALIDATIONS

 

14.1                           The Contractor must maintain a formal validation program for:

 

14.1.1                Facilities 

 

14.1.2                Equipment 

 

14.1.3                Methods 

 

14.1.4                Cleaning

 

14.1.5                  Process

 

34

 

14.2                           Validations may be prospective, concurrent or retrospective but in all cases, critical parameters and acceptance criteria will be documented.

 

The following is a listing of BMS Pharmaceuticals, Medical Imaging, Quality Department contacts.

 

·                  Dennis M. Brown, Vice President, Quality, (978) 671-8499

·                  William D. Mann, Director, Quality Assurance (978) 671-8375

 

35

 

EXHIBIT F

 

List of NA Accounts on the Effective Date of This Agreement

 

·                  ****

·                  ****

·                  ****

 

36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]